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The intracellular storage of nutrients and their subsequent release is an 
important physiological mechanism through which the organism obtains 
energy in the absence of a continuous feeding. Multiple hormones are 
involved in controlling the uptake, utilization, storage, and release of 
nutrients. In particular, glucose, a small, polar and, thus, water-soluble 
monosaccharide, is an important nutrient which exerts a critical role in the 
physiological functioning since it represents the mainly energetic source 
for all cell’s biosynthetic reactions. Blood glucose is easily measured and 
provides an accurate guide to the balance of insulin and the counter-
regulatory hormones. After a meal, complex carbohydrates are broken 
down to simple sugar in the Gastrointestinal (GI) tract by the action of 
glucosidase. Simple sugar, as glucose, are then absorbed by GI epithelial 
cells and transported into the blood to metabolic organs, such as the 
pancreas. The absorption of glucose from β-pancreatic cells stimulates 
insulin secretion. Transported into the bloodstream, insulin acts on its own 
receptor in target tissues, in particular liver, muscle and adipose tissue, to 
promote glucose uptake and storage as glycogen or triglyceride [1]. 
Insulin induces an the storage of glucose when there is an excess of this 
monosaccharide in the bloodstream; in muscle and liver, glucose is stored 
as glycogen, through the glycogen-synthesis mechanism, while in adipose 
tissues insulin promotes glucose conversion in triglycerides. On the 
contrary, when blood glucose concentration is low, pancreas releases 
glucagon from the α-pancreatic cells, which, opposite to insulin, promotes 
both hepatic production of glucose, through gluconeogenesis, and 
glycogen breakdown, through glycogenlysis, increasing blood glucose 
levels to the physiological condition. Even if, physiologically, insulin and 
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glucagon are the two most important hormones controlling glucose 
homeostasis, other hormones are involved in this equilibrium. Insulin 
action is potentiated by Glucagon-like peptide-1 (GLP-1) from the GI tract 
which enhances insulin release in response to an ingested meal, by 
amylin involved in the suppression of endogenous production of glucose 
from the liver and Peroxisome Proliferator-activated Receptors γ (PPARγ) 
in adipocytes which sustains insulin effect promoting the conversion of 
glucose to triglycerides. Moreover, the hormone leptin also plays an 
important role in the neuroendocrine response to energy storage and 
long-term energy balance suppressing the appetite. Conversely, the lack 
of leptin, as occurs in prolonged starvation, results in persistently 
increased appetite and suppression of energy-utilizing functions. On the 
other hand, glucagon effect is sustained by catecholamine 
(norepinephrine and epinephrine from the sympathetic nervous system 
and adrenal medulla), glucocorticoids (cortisol from adrenal cortex) and 
growth hormone (from the pituitary gland). They oppose the action of 
insulin as counter-regulatory hormones and raise blood glucose 
concentrations.  
Thus, the balance between insulin and the counter-regulatory hormones is 
important to maintain the blood glucose levels within a physiological 
narrow range, 70-120 mg/dl. The alterations of these levels could induce 
hypoglycemia (glucose levels lower than 70 mg/dl) or hyperglycemia 
(more than 120mg/dl), both representing pathological condition. 
Hypoglycemia is dangerous because organs, particularly the brain, 
depend on a constant supply of glucose for proper functions. The 
possibility to store glucose or to use triglyceride for energy is completely 
absent is Nervous System. The brain  cannot use fatty acids for energy 
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because they do not cross the blood-brain barrier, so it needs a 
continuous supply of the monosaccharide, otherwise, a low intake of 
glucose leads to permanent damage and death of nervous cells. 
Conversely, chronic hyperglycemia is toxic to many cells and tissues. 
When glycemia exceed the value of 126 mg/dl, reaching values of 180-
200 mg/dl, means that physiological regulation of blood glucose has been 
completely altered inducing a pathological state, firstly recognized with 
appearance of glucose in the urine, and then showing other severe 
symptoms for diagnosis. This pathological condition is represented by 
diabetes mellitus. Mostly, this disease is caused by the alteration of the 
physiological insulin-glucagon axes. In particular diabetic patients show an 
absolute or relative deficiency in insulin with consequent increase in 
glucagon values  and glucose concentration levels. The hyperglycemic 
condition in diabetes triggers to many other complications, the most 
common are the cardiovascular disease (CVDs), which represent the 
major cause of morbidity and mortality in diabetic patients.  
Nowadays, antidiabetic drugs which increase the insulin release and its 
action in controlling blood glucose levels, already ameliorate the 
cardiovascular profile, however these treatments do not completely 
restore the physiological vascular reactivity. Nevertheless, modern 
antidiabetic therapies include particular molecules which have a direct 
vascular beneficial effect through a blood glucose control independent 
manner. These class of drugs are represented by Dipeptidyl peptidase-IV 
(DPP-IV). The molecular mechanism through which these molecules act 
to restore vascular homeostasis is not yet clear. On this vision has been 
focused my PhD project, evaluating the beneficial effect of DPP-IV, 
antidiabetic drugs, in the vascular homeostasis.    
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1.1 Glucoregulatory hormones 
1.1.1 Insulin-Glucagon axis 
Insulin and glucagon are two protein hormones produced by the pancreas. 
The pancreas is a gland attached to the digestive system, formed by an 
exocrine and endocrine part. The exocrine pancreas is composed by 
acinar cells which synthesize and secrete the digestive enzymes (trypsine, 
chymotrypsin, elastase, amylase and others) involved in breaking down 
the food into simpler components that can be absorbed by the intestine. 
Scattered within the exocrine tissue  are nearly one million small islands of 
endocrine tissue that secrete hormones directly into the blood. These tine 
endocrine glands, collectively called Islets of Langerhans, contains 
different cell types that secrete different hormones: α-cells release 
glucagon; β-cells release insulin and amylin; δ- release somatostatine and 
gastrine; and PP cells release pancreatic polypeptide. Insulin and 
glucagon are the most important pancreatic glucoregulatory hormones. 
After their synthesis and release in the bloodstream, they reach their 
target organs, especially the liver, the muscles and the adipose tissue 
where act to regulate both the intake and production of glucose. 
Insulin is a small protein composed of two polypeptide chains containing 
51 amino acids released from the β-pancreatic cells. In particular, insulin 
is synthesized in the rough endoplasmic reticulum as a precursor protein 
called proinsulin. Proinsulin is then processed into the mature peptide 
hormone. The increase of blood glucose concentration is the stimulus for 
insulin release from pancreatic cells. When blood glucose concentration 
are high, β-pancreatic cells absorb glucose from the bloodstream through 
a specific plasma membrane transporter GLUT-2. In the cytosol glucose is 
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phosphorylated to glucose-6-phosphate  and thereby enters the glycolytic 
pathway generating ATP and increasing ATP/ADP ratio in the β-cells. The 
ATP/ADP ratio modulates the activity of a membrane spanning ATP-
sensitive K+ channels. When open, K+/ATP channels hyperpolarize the 
cell by allowing an outward flux of K+ with consequent inhibition of insulin 
production; on the contrary, when closed, the cell depolarizes and insulin 
is released. These channels are octameric structures containing four 
subunits of Kir6.2 and four subunits of the sulfonylurea receptor, SUR1. 
The kir6.2 tetramer forms the pore of the K+/ATP channels, while the 
associated SUR1 proteins regulate the channel’s sensitivity to ADP and 
other pharmacological agents. When Kir6.2 binds ATP the K+ 
conductance is inhibited, then voltage-gated Ca2+ channels are activated 
and the K+ current is directed to the extracellular space. Moreover, the 
rapid increase in intracellular calcium stimulates insulin exocytosis 





               
Figure 1.1 Mechanism of insulin release from β-cells.  
 
In addition to blood glucose, nutrient sugars, amino acids, and fatty acids 
increase the intracellular ATP/ADP ratio and thereby stimulate insulin 
release. Moreover, particularly involved in insulin release are also incretin 
hormones, such as Glucagon like peptide-1 (GLP-1) and Glucose-
dependent insulinotropic polypeptide (GIP). These hormones constitute 
the endogenous incretin system and they are both secreted from the 
intestine on ingestion of glucose or other nutrient. There are involved 
indirectly in the regulation of blood glucose stimulating insulin secretion 
from pancreatic-β-cells by the inhibition of K+/ATP channels activity. 
Once released insulin exerts its actions through binding to specific 
receptors present on many tissues of the body, including fat, liver and 
muscle cells. Insulin receptor is a glycoprotein consisting of four disulfide-
linked subunits, including two extracellular α-subunits and two β-subunits. 
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Each of the β-subunits is composed of short extracellular domain, a 
transmembrane domain, and an intracellular tail that contains a tyrosine 
kinase domain. The binding of insulin to the extracellular portion of the 
insulin receptor activates the intracellular tyrosine kinase, resulting in an 
auto-phosphorylation  of tyrosine on the nearby β-subunit and the 
phosphorylation of intracellular insulin receptor substrate proteins (IRS) 
such as the phosphatidylinositol 3’-kinase (PI3-kinase). Since the primary 
action to induce “glucose disappearance”, insulin signaling stimulates the 
translocation of insulin-responsive glucose transporter, GLUT-4, from 
intracellular vesicles to the cell surface. GLUT-4 translocation increases 
the uptake of glucose reducing its levels in the bloodstream. Moreover, 
especially in liver, insulin is able to activate glycolysis and glycogen 
synthesis, which are involved respectively in the degradation and store of 
glucose. Indeed, hepatic cells represent the most important source of 
endogenous glucose. Here, insulin promotes the phosphorylation of 
glucose into glucose 6-phosphate, which can be further metabolized and 
enter the degradation process, or it can be converted into glucose 1-
phosphate and enter the route of glycogen synthesis. In accordance to its 
physiological function to reduce blood glucose concentration, insulin also 
inhibits the gluconeogenesis process in hepatocytes, suppressing the 
Phosphenolpyruvate carboxykinase (PEPCK) activity. Since this enzyme 
does not undergo a post-transcriptional regulation, it can be activated or 
inhibited only as a result of changes of its mRNA. Insulin alters the 
acetylation of the gene coding for PEPCK, repressing its expression and 
then the activity. Leading to its capability to reduce blood glucose levels, 
insulin simultaneously inhibits glucagon secretion from pancreatic α-cells, 
thus signaling the liver to stop producing glucose via glycogenolysis and 
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gluconeogenesis. Moreover, in adipose tissue, insulin promote the  store 
of glucose and fatty acids as triglyceride. This process is enhanced by the 
activation of other lipogenic enzyme, including pyruvate kinase, pyruvate 
dehydrogenase, acetyl-CoA carboxylase and glycerol phosphate acyl-
transferase, and the deactivation of hormone-sensitive lipase, which 
degrades triglycerides. 
Conversely, glucagon has a totally opposite effect compare to insulin 
promoting mobilization glucose. When plasma glucose levels are low, 
glucagon mobilizes glucose, fat and protein from storage as energy 
sources. Glucagon acts binding  to its G protein-coupled receptor on 
plasma membrane leading to an increase of cyclic – Adenosin 
Monophosphate (cAMP) and activation of protein kinase A, a 
serine/threonine kinase. The primary action of glucagon is on the liver 
where it stimulates the breakdown of glycogen to glucose and the 
production of glucose from amino acids. In addition, acting on adipose 
tissue, it stimulates the release of free fatty acids and directs their 
metabolic fate in the liver. Rather than being used for the synthesis of 
triglycerides, these free fatty acids are shunted towards β-oxidation and 
the formation of ketoacids. Thus, glucagon is both a hyperglycemic and a 
ketogenic hormone. Besides low glucose and high insulin levels, glucagon 
secretion is also stimulated by sympathetic nervous system activity, 
stress, exercise and high plasma levels of amino acids indicating  a state 
of starvation. 
Insulin hypoglycemic effect is therefore countered by the hyperglycemic 
action of glucagon. The increase of one of the two hormones effect varies 
over time depending on the organism needs, and always has the purpose 
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of maintaining the blood glucose values in a constant and physiological 
range (Figure 1.2). 
         
       Figure 1. 2 insulin and Glucagon regulation of bloodstream glucose levels 
 
1.1.2 Amylin 
Amylin, or islet amyloid polypeptide (IAPP), is a 37-residue peptide 
neuroendocrine hormone. It is co-secreted with insulin from the 
pancreatic β-cells in the ratio of approximately 100:1 in response to 
nutrient stimuli [2]. Amylin is processed from an 89-residues coding 
sequence called Proislet Amyloid Polypeptide (proIAPP). Synthesized in 
10	  
	  
pancreatic  β-cells as a 67 amino acid, proIAPP under goes to post-
translational modifications including protease cleavage to produce amylin. 
Insulin and amylin are co-secreted following a meal. This has been 
confirmed by some studies in humans which demonstrate that the release 
of amylin and its plasma concentration is similar to insulin, with a low 
activity in the fasting state, and an increased response to nutrient intake 
[2]. Amylin in physiologically involved in the control of glycaemia levels 
and its glucoregulatory actions complement those of insulin. While insulin 
regulates the rate of glucose disappearance, amylin's metabolic function 
is well-characterized as an inhibition of the appearance of nutrient, 
especially glucose, in the plasma.  
As a neuroendocrine hormone, amylin exerts its action binding receptor 
within the central nervous system. In particular, this hormone slows  
gastric emptying and inhibits the release of digestive secretion, such as 
gastric acid, pancreatic enzymes, and bile ejection, resulting in a reduction 
in food intake. Appearance of new glucose in the blood is also reduced by 
inhibiting secretion of the gluconeogenic hormone glucagon, but this effect 
it is not mediated during insulin-induced hypoglycemia. Thus, following a 
rise of glucose concentration, amylin help insulin to rapidly restore the 








Somatostatin has 14-and 28 amino acids form that are selectively 
produced in pancreatic δ-cells, the gastrointestinal tract, and the 
hypothalamus. In the regulation of glycaemia levels, somatostatin inhibit 
the secretion of pancreatic insulin and glucagon, also this hormone reduce 
the GI motility and the release of various GI hormones. The stimuli for 
pancreatic somatostatin release are similar to those for insulin, such as 
high plasma levels of glucose, amino acids and fatty acids. 
1.1.4 Glucagon-Like Peptide-1 (GLP-1) and Gastric Inhibitory 
Polypeptide (GIP) 
GLP-1 and GIP are incretin hormones released from the enteroendocrine 
cells of the GI tract. After a meal GLP-1 and GIP are released in the 
bloodstream and they are particularly direct on pancreatic β-cells, where 
augments insulin secretion in response to an oral glucose load while on α-
cells GLP-1 and GIP suppress glucagon secretion. Moreover, GLP-1 acts 
in the stomach to delay gastric emptying and at hypothalamus to decrease 
appetite. Through all these mechanisms both GLP-1 and GIP show their 
glucoregulatory actions and thus directly participate in the regulation of 
blood glucose levels. 
 
1.2 Incretin System 
By the late 1960s, Perley and Kipnis and have other demonstrated that 
the ingestion of glucose caused a more potent release of insulin then 
glucose infused intravenously [3]. This effect is called “incretin effect”, and 
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is mediated by incretin hormones released from the gut which, not only 
affect insulin release, but also regulate gastric emptying and gut motility 
hormones, resulting in a reduction of blood glucose concentration after a 
meal. 
Glucagon-Like Peptide-1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP) 
represent the two primary incretin hormones. These hormones are both 
secreted from the intestine on ingestion of glucose or other nutrient to 
stimulate insulin secretion from pancreatic-β-cells (Figure 1.3).  
GLP-1 is produced primarily in enteroendocrine cells (L cells) of the distal 
small bowel (ileum). GLP-1 is encoded by glucagon gene to form pro-
glucagon which is alternatively processed into glucagon in pancreatic–
cells or GLP-1 and other peptides in gut L-cells. Blood levels of GLP-1 are 
low during the fasting state and rise after a meal. On the other side, GIP is 
a 42-amino-acid hormone secreted from K cells of the upper small 
intestine. Originally its action was associated to the inhibition of gastric 
acid secretion [4], later it has been found that GIP administration 
stimulates insulin secretion in healthy volunteer acting directly on 
pancreatic islets [5]. Moreover, it has also been shown that the increase of 
insulin release mediated by GIP is glucose-dependent, and for this reason 
the hormone has renamed as Glucose-dependent Insulinotropic 
Polypeptide [6] 
Since the immunological inhibition of GIP does not abolish insulin activity 
in gut extracts, GIP couldn’t be the only incretin hormones regulating 
insulin release and activity. Indeed, from the L cells of the lower intestine 
and colon is release GLP-1 as a second incretin hormone acting on 
pancreatic islets and stimulates insulin secretion from β-cells. 
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Both GIP and GLP-1 exert their insulinotropic effect by binding to their 
specific receptors, the GIP receptor (GIPR) and the GLP-1 receptor (GLP-
1R) on β-pancreatic cells. These receptors belong to the G-protein 
coupled receptor family, activating adenylate cyclase and increasing 
levels of intracellular cyclic adenosine monophosphate (cAMP) in 
pancreatic β-cells, thereby stimulating insulin secretion glucose-
dependently. In addition to their insulinotropic effect, GIP and GLP-1, play 
critical and several roles in various biological processes in different tissues 
and organs that express GIPR and GLP-1R, including the pancreas, bone, 
fat and brain [7]. Nevertheless, these hormones have a short half-life in 
the circulation, 1-2 minutes, due to enzymatic degradation by Dipeptidyl 
Peptidase-4 (DPP-4). Through the activity of DPP-4, incretin hormones 
are degraded in their inactive metabolites, losing their capability to 
regulate glucose homeostasis. For this reason, trying to reduce the blood 
glucose levels in pathological condition has been introduced in the 
pharmacological therapy drugs that act on the incretin system. Some of 
these drugs are represented by incretin hormones mimetic molecules 
because they act as agonists of GLP-1 and GIP receptors with a longer 
half-life, however, mostly recent are the DPP-IV inhibitors. These 
molecules block the degradation of incretin hormones potentiating and 




Figure 1.3 Incretin system and regulation of blood glucose levels 
 
1.2.1 Insulinotropic actions of GIP and GLP-1  
Several studies have shown that GIP and GLP-1 stimulates insulin 
secretion from β-pancreatic cells through a glucose dependent way. It has 
been demonstrated that mice lacking the GIP receptor exhibited 
intolerance after an oral glucose load [8]. Anyway, in this experimental 
model the glucose intolerance was not severe, confirming the involvement 
of another incretin hormone which compensate the lack of GIP signaling. 
Indeed, several evidences have demonstrated that GLP-1 antagonists 
drastically reduce insulin secretion after nutrients intake. In addition, mice 
lacking of GLP-1 showed a severe and fasting hyperglycemic condition 
after glucose or nutrient load, due to a significantly reduction of insulin [9]. 
All these evidences confirm the role of GLP-1 and GIP in potentiating 
insulin secretion and activity. Both these hormones exert their 
insulinotropic effect by binding their own receptor expressed on the cell 
membrane of β-pancreatic cells. The bound between incretin hormone 
and receptor, allows an increase of intracellular cAMP levels, thereby 
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activating protein kinase A (PKA) and exchange protein activated by 
cAMP 2(EPAC2).  Activation of PKA and EPAC2 pathway induces: 
alteration of ion channel activity, elevated cytosolic calcium levels and 
enhanced exocytosis of insulin-containing granules [10]. In particular, PKA 
shuts down K+ channels by phosphorylation of the SUR1 subunit and  
facilitates membrane depolarization [11]  with consequent increase of  
intracellular Ca2+ levels through both voltage-gated Ca2+ channels (VDCC) 
and intracellular stores [12]. The increased of Ca2+ concentration triggers 
to two particular events: 
• fusion of insulin-containing granules with the plasma membrane 
releasing insulin in the extracellular environment from β-cells; 
• stimulation of adenosine triphosphate (ATP) synthesis in 
mitochondria, which closes K+ATP channels increasing cellular 
depolarization [13].  
On the other side, activation of EPAC2 mainly enhances the density of 
insulin-containing granules near the plasma membrane, facilitating insulin 
secretion from β-cells [14] (Figure 1.4).  
Insulin hormone, as we know, induces the intake of glucose from the 
circulating blood to the peripheral tissues but fasting state, physical 
exercises or nutrient intake with the diet, are all conditions with a different 
request of glucose intake from the blood, so the release of insulin changes 
following the needs of the organism. Incretin system also supports insulin 
action in these different conditions, giving its contribution in maintaining 




   
Figure 1.4 GLP-1 and GIP molecular mechanism involved in insulin release from β-
pancreatic cells 
 
1.2.2 Non-insulinotropic action of GIP and GLP-1 
Incretin hormones exert several physiological effects that can be, or not, 
related to their capability to increase insulin release and action.  
Since incretin hormones receptors are presented in adipocytes 
experimental evidences have shown that GIP regulates fat metabolism in 
adipocytes. Indeed, this hormone is able to enhance the insulin-mediated 
incorporation of fatty acids into triglycerides, activation of lipoprotein lipase 
and fatty acids biosynthesis in adipose cells [15] 
GLP-1 and GIP-mediated control on insulin release and glycaemia levels 
is also associated to the capability of these hormones in promoting β-
pancreatic cells proliferation and survival. In particular GLP-1, in addition 
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to its effect on expansion of islet cell mass, has antiapoptotic action 
(Figure 1.5). Farilla L. et al. have shown that GLP-1 reduced the number 
of apoptotic cells in the pancreas of Zucker diabetic rats [16] and that this 
effect is independent from glucose control and insulin secretion. Moreover 
activation of GLP-1R inhibits apoptosis of MIN6 cells (insulinoma cells) 
exposed to hydrogen peroxide in a cAMP- and PI3-K-dependent manner 
[17]. Intracellular increase of cAMP levels and the following activation of 
PI3K leads to the phosphorylation and inactivation of the proapoptotic 
peptide BAD. BAD is a pro-apoptotic member of the Bcl-2 family that can 
displace Bax from binding to Bcl-2 and Bcl-xl, resulting in cell death. GLP-
1R activation induces Bcl-2 and Bcl-X upregulation with an associated 
anti-apoptotic affect  [18]. These findings support the hypothesis that GLP-
1 is not only a growth factor for β-cells but also a powerful antiapoptotic 
agent ameliorating their function in pathological conditions such as 
diabetes [19]. 
Moreover, GLP-1, but not GIP, stimulates gene transcription and insulin 
biosynthesis in β-cells [20] (Figure 1.5) providing a continual supplies of 
insulin secretion when the pancreatic vesicles of storage are depleted 
[21]. 
The control of blood glucose levels after a meal mediated by GLP-1 is not 
only related to its effect in insulin release and biosynthesis, but seems to 
be associated also to its capability in suppressing glucagon biosynthesis 
and release in pancreatic α-cells (Figure 1.3). Certainly, this is an indirect 
effect mediated by insulin, but it can’t be excluded a direct action of the 
incretin hormone, since GLP-1 receptors are expressed on pancreatic α-
cells [21].  
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The inhibitory effect of GLP-1 on glucagon secretion also seems to 
represent an important additional mechanism through which incretin 
hormones regulate blood glucose levels especially after a meal. However, 
GLP-1 has been shown to suppress glucagon levels only when glucose 
plasma levels are above fasting level [22]. This is clinically important 
because GLP-1 loses its inhibitory effect on glucagon secretion from α-
cells at hypoglycemic levels and does not attenuate the counter-regulatory 
responses to hypoglycemia. 
Moreover, the reduction of postprandial glucose excursion mediated by 
GLP-1 is due to an inhibitory effects of the hormone on gastrointestinal 
secretion and motility, in particular GLP-1 has been shown to reduce 
caloric intake and to enhance satiety probably involving central 
mechanism [23, 24] (Figure 1.5). Experimental studies with rodents made 
by Van Dijk and colleagues in 1999 have already proved that intra-
cerebroventricular administration of GLP-1 significantly reduced food 
ingestion, whereas concomitant injection of the GLP-1 receptor antagonist 
abolished completely this effect [25]. Today, 2016, it has been confirmed 
that Glucagon-like peptide-1 (GLP-1) affects appetite through the Central 
Nervous System (CNS). In order to investigate if CNS responses to 
feeding may be mediated by GLP-1, Ten Kulve JS and colleagues have 
evaluated the effects of endogenous GLP-1 and GLP-1 analogue, 
liraglutide, on CNS activation to chocolate milk receipt in healthy and 
diabetic volunteers. The findings obtained showed that in obese diabetic 
patients endogenous GLP1 and liraglutide improve the observed deficit in 
responsiveness to palatable food consumption then in healthy individuals, 
which may contribute to the induction of weight loss observed during 
treatment [26].  The exact mechanism by which peripheral GLP-1 
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modulate food intake is not been clarified yet. However the involvement of 
incretin system is supported by the presence of GLP-1 stores in neurons 
of nucleus of tracts solitaries, which project into thalamic and 
hypothalamic regions implicated in the control of food intake [27].  
Expression of GLP-1 receptor has been observed also in  distinct heart 
chambers and cell types, including cardiomyocytes [28], endothelial and 
vascular SMCs and has been associated with myocardial protection in the 
setting of ischemic/reperfusion injury [29] (Figure 1.5). Moreover, in the 
cardiovascular protective effects mediated by GLP-1 it has been included 
also the rapidly metabolite of the incretin hormones, GLP-1(9-36), which, it 
has been shown, induces vasodilatation via an NO/cGMP-associated 
mechanism that does not require a functional GLP-1R [30]. 
                                          




1.3 From the physiological condition to the pathology of 
diabetes 
Glucose regulation is a perfect orchestration of many hormones, both from 
pancreas and gut, that strongly work together in order to maintain 
glycaemia levels in a physiological range, 70 – 120 mg/dl. However, blood 
glucose concentration between meals can increase to 101-125 mg/dl 
which represents only an "impaired fasting glucose", but can also exceed 
to values more than 126 mg/dl meaning that the physiological regulation 
of blood glucose has been altered inducing a pathological state, firstly 
recognized with appearance of glucose in the urine, and then showing 
other severe symptoms for diagnosis. This pathological condition is 
represented by diabetes mellitus. The mainly responsible for this disease 
is the alteration of the physiological insulin-glucagon balance. While the 
increase of insulin secretion, lowers the blood glucose concentration 
values, establishing a state of hypoglycemia, on the contrary, the 
reduction of insulin values and the consequent increase in the glucagon 
values cause an increase in blood glucose concentration levels, and the 
triggering of  the hyperglycemic state of diabetes. 
The term diabetes derives from the greek word διαβαίνειν, that means 
going through and identifies some diseases characterized by polyuria 
(abundant production of urine) and polydipsia (abundant ingestion of 
water). Commonly the term is used to indicate a chronic condition, 
characterized by a high concentration of glucose in the blood due to a 
deficiency (absolute or relative) in the human insulin secretion or function. 
The use of the adjective diabetes mellitus comes from the Latin 
"sweetened with honey" and refers to the large amount of glucose that is 
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found in the urine of patients suffering from the disease. Although the 
mainly elements which identify the diabetic condition is represented by 
high blood glucose levels, it is important to highlight that this term is not 
only use for diabetes mellitus, but also identify another pathological 
condition which shows similar signs and symptoms, such as an excessive 
thirst and an excessive urination, called “diabetes insipidus”. Although 
they show similar symptoms, diabetes mellitus and insipidus born from 
different physiological alteration. While the mainly problem of diabetes 
mellitus is represented by the high blood glucose concentration due to an 
alteration of physiological insulin secretion and peripheral activity, 
diabetes insipidus is characterized by the deregulation of the response to 
antidiuretic hormone (ADH) which causes the inhibition of water 
reabsorption in the collecting ducts of the nephron, resulting in the 
production of copious amounts of dilute urine. Laboratory analysis show 
that in patients with diabetes insipidus the concentration of glucose in the 
blood and urine remains normal, and this is allow to differentiates diabetes 
insipidus from mellitus.  
 
1.4 Diabetes Mellitus 
In 1774, thanks to Matthew Dobson, it has been discovered that the sweet 
taste of the urine of patients suffering from Diabetes Mellitus (DM) was 
due to glucose contained in them [31]. This initial analysis was then 
followed by other studies that in 1910 suggested that people with DM 
were actually deficient in a particular substance produced by the 
pancreas, which he named as insulin, produced by the islets of 
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Langerhans located in the pancreas. Insulin, thanks to the work of 
Canadian researchers Frederick Banting and Charles Herbert Best, was 
isolated in 1921, and following this discovery it has been concluded that 
diabetes was an endocrine disease linked to a deficiency of insulin. From 
1935 to now, many studies have been done and in fact currently the DM 
disease results from a heterogeneous group of metabolic disorders that 
have hyperglycemia in common. Hyperglycemia can result from an 
absolute lack of insulin, like  in the type 1 diabetes mellitus (T1DM), also 
called insulin-dependent diabetes mellitus (IDDM), or from a relative 
insufficiency of insulin production in the face on insulin resistance, 
conditions that represents the type 2 diabetes mellitus (T2DM), also called 
non insulin-dependent diabetes mellitus (NIDDM).  
1.4.1 Type 1 Diabetes Mellitus 
Type 1 diabetes is usually diagnosed in children and young adults. This 
pathology was previously known as juvenile diabetes, and today is mainly 
know as “Insulin-Dependent Diabetes Mellitus”.  
Type 1 Diabetes Mellitus is a particular form of diabetes characterized by 
the autoimmune destruction of β-pancreatic cells. In absence of β-cells, 
insulin is neither produced nor released, and circulating insulin 
concentrations are near zero leading to pathological consequences. 
Indeed, in the absence of insulin, tissues fail to take up and store glucose, 
amino acids and lipids, even when there are high circulating plasma levels 
of these fuels. Moreover, the unavailability of insulin to promote nutrient 
entry into cells, coupled with the unopposed actions of counter-regulatory 
hormones, induces a starvation-like response by the cells and tissues of 
the body. Thus, glycogenolysis and gluconeogenesis proceed unchecked 
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in the liver, delivering glucose to the bloodstream even if its levels are 
already high. Contextually, muscle tissue breaks down protein and release 
amino acids, which travel to the liver as fuel for gluconeogenesis. In 
adipose tissue instead, triglycerides are broken down and release into the 
circulation. The derived fatty acids are then break down in the liver for use 
as gluconeogenic fuels and for export as ketone bodies that, accumulating 
in the plasma, increase the normal level of acidity, which, in turn, leads to 
abdominal discomfort, nausea, vomiting, rapid breathing, confusion and 
possible coma. All these events leads together to a drastically increase of 
blood glucose concentration, with reduction of kidney’s capacity to 
reabsorb glucose from the glomerular filtrate and a consequent osmotic 
dieresis as well as a “sweetening” of urine. This phenomenon causes the 
typical polyuria and subsequent polydipsia experienced by many diabetic 
patients. Contextually, although appetite it is stimulated, patients loss their 
weight because dietary nutrients are inaccessible.  
Type 1 Diabetes Mellitus accounts for between 5% and 10% of all 
diabetes cases [32]. Even if the number of people with DM type 1 is 
unknown, it has been estimated that globally about 80,000 children 
develop the disease each year. Moreover it has been assessed that the 
development of new cases depends on the country and region. Indeed, 
Japan and China represent the country with the lowest rates of the new 
cases per year; approximately 1 person per 100,000 per  year; finally  the 
highest rates are found in Scandinavia, where rates are closer to 35 new 
cases per 100,000 per year [33]. 
While it is well established that the patho-physiology of Type 1 DM is 
represented by the destruction of β-pancreatic cells, the causes of the 
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onset of the pathology are unknown. Blood analysis of diabetic patients 
show the presence of antibodies directed against antigens expressed at 
the level of cells that produce insulin, known as ICA, GAD, IA-2, IA-2B. 
For this reason, the Type 1 DM is also ranked among the so-called 
disease “autoimmune”, that is due to a direct immune reaction against the 
body itself, in this case against the own β pancreatic cells. This damage, 
mediated by the immune system, could be related to genetics or 
environmental factor, or can be associated to the activity of chemicals and 
drugs. Regarding the genetic factors, at least 20 different chromosomal 
regions have been linked T1DM susceptibility in humans, using genome 
screening, candidate gene testing, and studies of human homologues of 
mouse susceptibility genes. For this reason diabetic pathology can be 
inherited from parents. Indeed, it has been show that if one of the parents 
has T1DM the probability that the disease occurs in a child is 5-10%, 
otherwise if both parents are affected by the pathology the odds for 
children increased to 23%. Moreover, the risk of developing the disease 
depends also for the environments, which surround the children. Indeed, 
for identical twins, when one twin has type 1 diabetes, the other twin only 
shows the disease in the 30%–50% of the time. Thus for 50%-70% of 
identical twins where one has the disease, the other will not, despite 
having exactly the same genome; this suggests environmental factors, in 
addition to genetic factors, can influence the disease's prevalence. These 
can also reflects the reason why the rates of the diabetic pathology varies 
by country and region. Some chemicals and drugs also could be 
responsible for destroying pancreatic cells. Pyrinuron (Vacor), a 
rodenticide introduced in the United States in 1976, selectively destroys 
pancreatic beta cells, resulting in type 1 after ingestion. Pyrinuron was 
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withdrawn from the U.S. market in 1979 but is still used in some 
countries. Streptozotocin (Zanosar), an antibiotic and antineoplastic agent 
used in chemotherapy for pancreatic cancer, kills β-cells, resulting in loss 
of insulin production. Other pancreatic problems, including 
trauma, pancreatitis, or tumors (either malignant or benign) can also lead 
to loss of insulin production. 
1.4.2 Type 2 Diabetes Mellitus 
Type 2 Diabetes mellitus is the most common form of diabetic pathology, 
indeed it makes up  about 90% of cases of diabetes, with the other 10% 
due primarily to T1DM and gestational diabetes. T2DM appears in mature 
ages, typically affects individuals over 40 years old, although young adult 
and pediatric cases are rapidly increasing. Obesity is the single most 
important risk factor, and more than 80% of type 2 diabetic patients are 
obese. The disorder typically develops gradually without obvious 
symptoms at the onset. At the beginning it can be diagnosed  by elevated 
blood glucose levels, then, when the pathology became severe, appear 
the typical symptoms of polyuria and polydipsia. Despite the type 1, T2DM 
in the chronic phase is supported by combination of reduced insulin 
secretion and insulin sensitivity, defined insulin resistance. With increasing 
age and added weight, tissues that were once normally insulin-responsive 
become relatively refractory to insulin action and require increasing insulin 
levels to respond appropriately. In addition, the loss of β-cells through 
increased apoptosis or for a decreases renewal, cause a failure in 
satisfies the need of insulin to compensate the insulin resistance. Thus, 
type 2-diabetes cannot be attenuated by insulin administration, as type 1, 
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and for this reason it also named “Insulin-Non-Dependent Diabetes 
Mellitus”. 
Insulin levels that are incapable of compensating for insulin resistance 
result in an imbalance between the actions of insulin and those of the 
counter-regulatory hormones, which may contribute to hyperglycemia and 
dyslipidemia as the liver and the adipose tissue inappropriately mobilize 
fuels from tissue stores. Indeed, insulin resistance occurs primarily within 
the liver, muscles, and fat tissue. Under physiological conditions, acting on 
the liver, insulin suppresses the release of glucose. On the contrary, in 
type 2 diabetes the insulin resistance induces the liver to releases 
continuously glucose in the blood resulting in higher blood sugar to 
become hyperglycemia. Furthermore, the decreased sensitivity of fat cells 
to insulin, activates the process of lipolysis, with consequent increased 
concentration of free fatty acids in the blood that get worse the 
pathogenesis of diabetes, reducing the uptake of glucose into skeletal 
muscle and further promoting the release of glucose by the liver.  
The development of type 2-diabetes is caused by a combination of 
lifestyle and genetic factors [34, 35]. While some of these factors are 
under personal control, such as diet and obesity, other factors are not, like 
the increasing age, female gender, and genetics. 
Lifestyle factors have an important relevance in the development of type 2 
diabetes, including obesity, being overweight, lack of physical activity, 
poor diet, smoke,  stress, and urbanization [35, 36]. Obesity is  the most 
common condition related to the development of diabetic pathology. 
Indeed, the excessive amount of fat cells in the obese patients leads to an 
excessive amount of insulin required, and when this request is chronic the 
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quantity produced start to be not enough to satisfied body's needs. This is 
the reason why a lack of exercise is believed to be the responsible of the 
7% of cases [37, 38]. 
Moreover, although type 2 diabetes is not considered as an autoimmune 
disease, elements of both the innate (macrophages and mast cells) and 
adaptive (T regulatory cells, Th1 cells, CD8+ T cells) immune system are 
present in obese adipose tissue and may play roles in the pathogenesis of 
insulin resistance.  
Dietary factors also influence the risk of developing type 2 diabetes, 
indeed consumption of sugar-sweetened drinks in excess is associated 
with an increased risk [39, 40]. Eating lots of white rice also appears to 
play a role in increasing risk. 
In most cases all of these lifestyle factors are also associated with genetic 
alterations related to several genes (polygenic disease) involved in insulin 
production and glucose metabolism. More than 40 genes have now been 
identified, and most have predominant actions in the β-cells. Few of the 
identified type 2 diabetes genes confer risk for either obesity or insulin 
resistance. Therefore, insulin-sensitive patients with type 2 diabetes have 
a strong predisposition to β-cells failure. Mild or early type 2 diabetes can 
be also unmasked in predisposed individuals by transient periods of 
insulin resistance, as occurs during the treatment with glucocorticoids or 
pregnancy, which show the onset of the gestational diabetes. 
1.4.3 Pharmacological treatment of diabetes mellitus 
Therapeutic agents are available to modify most steps in the regulation of 
glucose homeostasis. The major goal of the pharmacological therapy of 
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diabetes is to normalize metabolic parameters, such as blood glucose, in 
order to reduce the risk of long-term complication.  
For type 1-diabetes, the pharmacologic strategy is to administer a 
sufficient amount of exogenous insulin to achieve normoglycemia, without 
inducing hypoglycemia. Human insulin is manufactured by bacterial 
recombinant DNA technology. Because the insulin molecule has a short 
half-life of only few minutes in the circulation, for the type 1 diabetes 
treatment have been formulated many preparation which release the 
hormone slowly in the way that its activity can be prolonged. The available 
insulin forms provide 4 rates of onset and duration: ultra-rapid onset, rapid 
onset with short action, intermediate onset and action and slow onset with 
short action. All insulin preparations contain zinc and the ratio of this 
molecule is the mainly responsible for the rate of release of the hormone 
from the site of administration and the duration of action. Although insulin 
represents the first and also best choice to restore plasma glucose 
concentration it is important that patients, during the treatment need to 
follow appropriate dietary and also have to pay attention to all the factors 
that change insulin requirements, such as physic exercises, infections, 
stress and deviation from the regular diet in order to avoid a dangerous 
hypoglycemic event.  
On the other side, treatment of type 2 diabetes is more complex and 
involves several target which can be modify to re-stabilize glucose 
homeostasis. Firstly, obese patients should to reduce body weight and 
increase exercises in order to improve the insulin sensitivity. These 
changes in the lifestyle can be then associated with a pharmacological 
approach through using oral active antidiabetic drugs: 
29	  
	  
-­‐ Insulin Segretagogues, such as Sulfonylureas and Meglitinides 
-­‐ Biguanides 
-­‐ Amylin analogue 
-­‐ Insulin sensitizers as Thiazolidinediones 
-­‐ α-glucosidase inhibitor 
-­‐ Incretin therapy which act trough GLP-1 analogue or, more recent, 
DPP-IV inhibitor 
Insulin Segretagogues 
Insulin segretagogues are drugs which act stimulating the release of 
insulin from pancreatic β-cells, with consequent increase of circulating 
insulin to levels sufficient to overcome the insulin resistance. This 
mechanism is typical of Sulfonylureas and Meglitinides, two antidiabetic 
classes of drugs, used in the therapy of type 2 diabetes. Physiologically, 
after a meal, the glucose up-taken from the blood into β-pancreatic cells, 
is metabolized releasing ATP, which consequently inhibits K+/ATP, 
channels binding the Kir.6 subunits. Indeed, Sulfonylureas bind to K+/ATP 
channels in β-cells involving another subunit called SUR1. The bind with 
SUR induces the inhibition of the channel as well, with membrane 
depolarization, Ca2+ influx and fusion of insulin-containing vesicles with 
the plasma membrane releasing insulin in the blood stream. The 
increased release of insulin in type 2 diabetic patients compensates the 
increased tissues request of the hormone in the condition of an increased 
insulin-resistance. Nevertheless, this action mediated by Sulfaniluree has 
to be continuously monitored since one of the major adverse affect is the 
hypoglycemia resulting from the over-secretion of insulin. Thus, these 
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medications should be used continuously in patients who are unable to 
recognize or respond appropriately to hypoglycemia, such as those with 
impaired sympathetic function, mental status changes, or advanced age. 
Like Sulfonylureas, Meglitinides stimulate insulin release by binding SUR1 
and inhibiting the β-cell K+/ATP channel. Although Sulfonylureas and 
Meglitinides both act on the SUR1 subunit, these two class of drugs bind 
to distinct regions of the SUR1 molecule. Obviously, since the the 
molecular effect is the same, also the adverse-effect profile is similar in 
these two class of anti-diabetic, with a high risk of hypoglycemic episodes. 
Biguanides 
The insulin-resistance condition in T2DM causes a greater glucose 
production from the liver, increasing hyperglycemia and its pathological 
consequences. For this reason, another pharmacological approach in this 
pathology is represented by drugs, which are able to reduce the hepatic 
glucose production, such as the Biguanides. The one from this class of 
drugs, which is the most efficient and used in the anti-diabetic therapy, is 
the metformine that acts to decrease glucose production in the liver by 
activating the energy-regulating enzyme AMPK. By triggering hepatic 
AMPK, metformine inhibits gluconeogenesis, fatty-acid synthesis and 
cholesterol synthesis. Through this mechanism, metformine increases 
insulin signaling and is affective in lowering blood glucose levels in type 2 
diabetic patients. Nevertheless, because to its capability in decrease the 
flux of metabolic acids, a serious adverse effect of metformine, as of all 
the Biguanides, is the lactic acidosis due to the accumulation of lactic acid 
to dangerous levels for the patients. On the other hand, since Biguanides 
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do not directly affect insulin secretion, their use is not associated with 
hypoglycemia, as happen for Sulfaniluree and Meglitinides.  
Amylin analogue: Pramlintide 
In the post prandial phase, β-pancreatic cells co-secreted with the insulin 
another glucoregulatory hormone, the amylin, which specifically 
participates in the regulation of blood glucose levels after the meal 
sustaining the activity of insulin. Type 1 and type 2 diabetes are both 
characterized by a relatively lack of amylin, thus in order to restore the 
glucose metabolism in these patients, has been introduced a new drugs in 
the anti-diabetic therapy, represented by pramlintide, an analogue of 
amylin. Pramlintide was designed as a stable analogue of the human 
amylin and, as the endogenous hormone, is able to slows the gastric 
emptying, reduces postprandial glucagon and glucose release, and 
promotes satiety. Through these effects, pramlintide, can sustain the 
action of the remaining amount of insulin present in the diabetic patient, or 
can collaborate with other antidiabetic drugs, such as Sulfonylureas, 
Biguanides and other in order to improve their hypoglycemic effect and 
improve the glucose metabolism. 
Insulin sensitizers: Thiazolidindiones 
Rosiglitazone and pioglitazone are the two currently available 
Thiazolidindiones (TZDs) used in the therapy of type 2 diabetes. These 
drugs are insulin “sensitizers” and enhance the action of insulin at target 
tissues without directly affect insulin secretion. The Thiazolidindiones are 
synthetic ligands, which stimulate the peroxisome proliferator-activated 
receptor-gamma (PPARγ-receptor). PPARγ is a nuclear receptor, which 
regulates the transcription genes encoding protein involved in 
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carbohydrate and lipid metabolism. By activating PPARγ, TZDs promote 
fatty-acid up-take and storage in the adipose tissue rather than in skeletal 
muscle and liver. The decrease in muscle and liver fat content makes 
tissues to be more sensitive to insulin increasing the up-take of glucose 
from the blood. Moreover, these drugs inhibit the hepatic gluconeogenesis 
suppressing hepatic glucose production typical of the disease. 
α-glucosidase inhibitors  
Complex starches taken through the diet, such as oligosaccharides and 
disaccharides, have to be metabolized to smaller monosaccharides in 
order to be assimilate in the bloodstream. This is a necessary process, 
which happens in the intestine, and it’s mediated by the enzyme α-
glucosidase. Acarbose and miglitol are carbohydrate analogs that act 
within the intestine to inhibit α-glucosidase. This effect results in a slow of 
monosaccharide’s absorption with consequent reduction of the 
postprandial hyperglycemia. Both drugs can be used as monotherapy, but 
since continuous regulation of blood glucose levels in diabetic patients 
cannot be maintain by the only action α-glucosidase inhibitors, they are 
used also in combination with other antidiabetic drugs. The primary 
adverse effect includes flatulence, diarrhea and abdominal pain resulting 
from increased fermentation of unabsorbed carbohydrate by bacteria in 
the colon. Moreover, hypoglycemic event in patients treated with α-
glucosidase inhibitors should be controlled directly with oral glucose 
because the absorption of the other complex carbohydrates is delayed. 
GLP-1-based “Incretin” therapy 
Incretin system plays an important role in the regulation of blood glucose 
levels through the action of incretin hormones, GLP-1 and GIP, released 
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from the gut after a meal. Incretin hormones show hypoglycemic actions 
through an increased release of insulin and reduction of circulating 
glucagon, but these effects last very few since their short half-life. Indeed, 
GLP-1 and GIP after their release are metabolized in inactive molecules in 
2-3 minutes by Dipeptydil peptidase-IV enzyme (DPP-IV). Presently, the 
available incretin-based therapies for diabetes mellitus include the GLP-1 
receptor agonists or incretin analogs, which are resistant to DPP-4 
degradation, and DPP-4 inhibitors; the mechanisms of action of both 
involves the increase of the endogenous effects of GLP-1. Since one of 
the physiological effect of incretin hormones is to increase the release of 
insulin from the pancreas, these drugs are only used in type 2 diabetes, 
and not type one where the capability of β-pancreatic cells to release 
insulin has been compromised. Exenatide is a GLP-1 analogue, originally 
isolated from the salivary gland of the Gila monster. This molecules, has 
been approved for use in type 2 diabetics in the United States in 2005. As 
a GLP-1 analogue, exenatide has several modes of action that benefits 
patients with diabetes: it increases secretion of insulin by pancreatic β-
cells in a glucose-dependent manner; it suppresses secretion of glucagon 
by pancreatic α-cells; it slows gastric emptying and thereby slows the rate 
of nutrient entry into the circulation with consequent reduction of the 
appetite. Despite the efficient action of these class of drugs in maintain the 
glycemia within physiologically and safety levels, there is another way to 
improve and sustain the hypoglycemic effect of the incretin system, the 
use of DPP-IV. DPP-IV is the endogenous enzyme responsible of incretin 
hormones degradation with consequent reduction of their physiological 
effects. The inhibition of DPP-IV prolongs the half-life of incretin 
hormones, in particular of the endogenous GLP-1, potentiating its 
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hypoglycemic effect. Indeed, inhibition of DPP-IV and the consequent 
increase of circulating GLP-1, induces an enhanced release of insulin 
from pancreas in a glucose-dependent manner and a decrease of 
glucagon concentrations. The most common DPP-IV inhibitors used in 
T2DM are sitagliptin and saxagliptin, which were Food and Drug 
Administration (FDA) approved in 2006 and 2009 respectively. Moreover, 
another inhibitor recently introduced in therapy and equally effective is 
linagliptin, FDA approved in 2011.  
1.4.4 DPP-IV enzyme and its inhibitors 
DPP-4 is a 766 aminoacid transmembrane glycoprotein, also known as 
adenosine deaminase complexing protein 2 or CD26, and DPP-4 
inhibitors are cyanopyrrolidines with key interactions with the DPP-4 
complex that allow for competitive inhibition. This enzyme is expressed on 
the surface of several cell types such as monocytes, lymphocytes [41] and 
vascular endothelial cells [42]. Specifically, DPP-IV is a serine 
aminopeptidase enzyme, which inactivates GLP-1, GIP and other proteins 
in vivo via dipeptide cleavage of the N-terminal amino acid. In order to 
show its catalytic activity is necessary the dimerisation of the enzyme for 
its activation, than occurs the glycosylation to finally induce its 
physiologically effects. Moreover, DPP-IV acts on several proline or 
alanine containing peptides, such as growth factors, chemokines, 
neuropeptides and vasoactive peptides [43]. For this reason, since DPP-
IV not only regulate the activity of incretin hormones on blood glucose 
regulation, but also of other endogenous mediators, inhibition of this 
enzyme mediates a wide range of pleiotropic effects, both positive and 
negative, independent of GLP-1. The currently available DPP-4 inhibitors 
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include sitagliptin, saxagliptin, linagliptin, vildagliptin and alogliptin. The 
first three are approved in the USA and throughout much of the world for 
the treatment of T2DM; vildagliptin has been approved for use in Europe 
and Latin America and alogliptin for use in Japan. Other members of this 
class are in phase III clinical trials, and include dutogliptin and gemigliptin. 
Currently, the drugs are predominately used as second- or third-line 
agents, typically after metformin or the combination of metformin-
sulfonylurea or metformin-thiazolidinedione. Moreover, DPP-4 inhibitors 
are well tolerated, with hypoglycemia only occurring when used in 
combination with sulfonylureas therapy. Indeed, they are also approved 
for use as monotherapy, mainly used in this setting in those who cannot 
tolerate or have active contraindications to metformin (e.g. chronic kidney 
disease). DPP-4 inhibitors may also have a unique role in elderly patients 
who face several precautions regarding the use of other anti-
hyperglycemic drugs due to their potential toxicities.  
1.4.5 Symptoms and complications of Diabetes mellitus 
The symptoms of diabetes mellitus are several and, in particular they 
depend on whether the pathology has the characteristics of T1DM and 
T2DM. In type 1-diabetes the onset of the disease is sudden. At the 
beginning, patients complain a widespread fatigue (asthenia), an intense 
thirst (polydipsia) and increase the amount of urine. These first symptoms 
are then followed by weight loss, dry skin and tendency to get sick 
frequently, such as the susceptibility to infections. While symptoms of 
T1DM are immediate and clear since the beginning of the disease, on the 
other side, T2DM has a slower onset, so the disease is usually diagnosed 
after clinical investigation carried out for other reasons. All these 
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symptoms are signs of the diabetic process and when the pathology well 
confirmed, is not good treated, they are accompanied by several clinical 
acute or chronic complications. Acute complications occur in short-term 
from the onset of the diabetes, while chronic complication comes after 
long time from the beginning of the pathology. In the first group are 
included: 
- Diabetic ketoacidosis, characterized by excessive concentration of 
ketone bodies in the blood due to insulin deficiency with consequent 
excess of glucagon. As we already know, under physiological conditions 
triglycerides are stored in VLDL (with particular lipoprotein transport 
function); in the conditions of fasting and excess glucagon accompanied 
to insulin deficiency, the cells are unable to use the plasma glucose as an 
energy source, exploit triglycerides and fatty acids transported in the 
blood. The latter, through the reaction of beta-oxidation, produce energy, 
but also high amounts of a molecule (acetyl-coenzyme A), from which the 
ketone bodies such as acetone, acetic acid and beta-hydroxy-butyric acid 
are obtained. Subsequently, these ketone bodies are poured in blood and 
cause the so-called diabetic ketoacidosis. Moreover, the inability to use 
glucose stimulates the production of hormones that in turn have a 
hyperglycaemic effect facilitating the endogenous glucose production via 
hepatic gluconeogenesis and glycogenolysis, further aggravating the 
hyperglycemic state and diabetic ketoacidosis. Moreover, hyperglycemia 
and ketosis induce a lowering of the pH of the blood, resulting in 
manifestations of nausea, vomiting, dehydration, polyuria, polydipsia, 
hypotension, drowsiness and coma.  
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- Hyperglycemic hyperosmolar state, is observed mostly in elderly 
patients in whom the diabetic condition is aggravated by recurring events 
(eg. Infections or stroke) and the ability to drink is reduced making 
impossible the compensation of water loss due to osmotic diuresis. It 
follows severe neurological symptoms due to dehydration of the cells, with 
convulsions and motor deficit. Laboratory tests show marked glycosuria in 
absence of ketone bodies in urine and extremely high blood sugar, usually 
above 1000 mg / dl, about twice as many values in ketoacidosis coma. 
On the other side, the long-term or chronic complications include: 
- Diabetic retinopathy is a damage to the small blood vessels supplying 
the retina with loss of the sight. In addition, people with diabetes are more 
likely to develop eye diseases such as glaucoma and cataracts. 
- Diabetic nephropathy, a progressive reduction of the kidney filtering 
function that, if untreated, can lead to renal failure until the need for 
dialysis and / or kidney transplant. 
- Diabetic neuropathy, which is one of the most frequent complications 
and according to WHO is manifested at different levels in 50% of 
diabetics. It can cause loss of sensation, of varying intensity pain and limb 
damage, requiring amputation in severe cases. It can lead to malfunctions 
of the heart, eyes, stomach and is a major cause of male impotence. 
- Diabetic foot,   which is correlated to  the modifications of the structure 
of blood vessels and nerves that cause ulceration and problems in the 
lower extremities, especially the foot. This may necessitate amputation of 




- Cardiovascular disease (CVD): From the point of view of the 
cardiovascular medicine, diabetes is considered a cardiovascular disease. 
Several epidemiological and pathological data demonstrate that diabetes 
is an independent risk factor for CVDs [44], listed as the mainly cause of 
death in of  people with diabetes. 
 
1.5 Vascular tone 
In combination with cardiac output, vascular tone determines the 
adequacy of perfusion of the tissue of the body. The importance of 
vascular tone is underscored by the wide spectrum of diseases are 
associated with altered vascular tone. A complex of molecular 
mechanisms is involved in the regulation of vascular homeostasis in the 
face of different stimuli. In particular, regulators of vascular tone act by 
influencing the actin-myosin apparatus of vascular smooth muscle cells. 
As in other muscle cells, the actin-myosin interaction leads to contraction 
and is regulated by intracellular calcium (Ca2+) concentration. Stimulation 
of vascular smooth muscle cells can increase the cytoplasmic Ca2+ 
concentration through two mechanisms: first, Ca2+ can enter the cell by 
way of voltage-gated Ca2+ -selective channels in the sarcolemma, then the 
increase of cytoplasmic Ca2+ can be elicited by the release of intracellular 
Ca2+ from sarcoplasmic reticulum.  Vasoconstriction, the contraction of 
vascular smooth muscle, is commonly initiated by the opening of voltage-
gated L-type Ca2+ channels in the sarcolemma during plasma membrane 
depolarization. When Ca2+ channels are open, a calcium ions flux goes 
into the cytoplasm and activates cytoplasmic calmodulin (CaM). The Ca2+-
CaM complex binds to and activates myosin chain kinase, which 
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subsequently phosphorylates myosin-II light chains. When the light chain 
is phosphorylated, the myosin head can interact with an actin filament, 
leading to the smooth muscle contraction. 
On the other side, the opposite reaction of the vessel to the contraction is 
the vasodilatation, the relaxation of the vascular smooth muscle. 
Vasodilatation occurs upon de- phosphorylation of the myosin light chain. 
De-phosphorylation is potentiated when Guanylyl Cyclase (GC) is 
activated inside the smooth muscle cells. Indeed, activated GC increases 
the production of cyclic guanosine 3’5’-mophosphate (cGMP) which 
stimulates cGMP-dependent protein kinase, called PKG inducing 
phosphorylation and than activation of myosin light chain phosphatase, 
involved in the de-phosphorylation of myosin light chain. De-
phosphorylation of myosin light chain inhibits the interaction of the myosin 
head with actin, leading to smooth muscle relaxation.  
Stimulation of vasoconstriction and vasorelaxation is governed by a wide 
variety of mechanisms, which involve an interaction between vascular 
smooth muscle cells and vascular endothelial cells. In particular, as a 
major regulator of vascular homeostasis, the endothelium has the 
important role of maintain equilibrium between vasodilation and 
vasoconstriction, moreover it is involved in regulate migration and 
proliferation of smooth muscle cells, fibrinolysis, thrombogenesis as well 
as the adhesion and aggregation of platelets [45]. Many vascular diseases 
are associated to an endothelium dysfunction which cause an alteration in 





1.5.1 Components of the vascular wall 
Blood vessels are composed of three layer: an intimal monolayer of 
endothelial cells, medial vascular smooth muscle and the adventitia, also 
called tuninca externa (Figure 1.6) 
 
 
Figure 1.6 Structure of a blood vessel wall 
 
Endothelial cells constitute the interior surface of the blood vessels of the 
entire vascular tree, from the heart to the smallest capillaries. The 
endothelium plays an essential role in the regulation of vascular tone, 
modulating both the basal and dynamic diameter of the vessels through 
the release of vascular mediators and by initiating endothelium-dependent 
hyperpolarization. Endothelial cells monolayer is then surrounded by the 
tunica media composted by an elastic membrane attached to a thick layer 
of smooth muscle cells, which are responsible of the contraction and 
vasodilatation of the vessels. Contraction of vascular smooth muscle cells 
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can be due by mechanical or pharmacological stimulus. Mechanical 
stimuli are represented by the increase of intraluminal pressure (myogenic 
tone) or the stretch of the vessels. On the other hand, pharmacological 
approach involves the bind of particular molecules to smooth muscle cells 
surface receptors. All these signaling lead to an increase of intracellular 
calcium levels and consequent vasoconstriction. The outermost layer of 
the blood vessel is characterized by the tunica externa, 
or tunica adventitia, composed entirely from connective fibers and 
surrounded by an external elastic lamina which functions to anchor 
vessels with surrounding tissues. This layer is often thicker in veins 
preventing collapse of the blood vessel, and also as veins are often more 
superficially located providing protection from damage. 
1.5.2 Endothelial function 
The endothelium is a monolayer of cells covering the vascular lumen. For 
many years this cell layer was thought to be relatively inert, considering it 
just a barrier between circulating blood and the underlying tissues. Now it 
has been recognized that endothelium is indispensable in preserve the 
physiological vascular homeostasis through a paracrine, endocrine and 
autocrine action [46]. Indeed, the endothelium participates in multiples 
vascular functions, such as the regulation of vessel integrity, vascular 
growth and remodeling, tissue growth and metabolism, immune response, 
cell adhesion, angiogenesis, fibrinolysis and thrombogenesis of platelets 
and vascular permeability [47]. Beside all these functions, endothelium 
shows its pivotal role in the regulation of vascular tone, controlling tissue 
blood flow [48]. The research in the past few decades has elucidated 
several molecular pathway through which the endothelium controls the 
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vascular tone. In particular, endothelial cells are responsible of release 
mediators which participate in the maintenance of vascular homeostasis 
[49]. Some of these are: the endothelium derived hyperpolarization factor 
(EDHF), Nitric Oxide (NO) [50] and prostacyclin (PGI2) [51], which are 
responsible of a vasodilatory and antiproliferative effects, while 
endothelin-1 (ET-1) [52], angiotensin II and reactive oxygen species 
(ROS) are the main mediators involved in the vasoconstriction events [53]. 
Moreover, endothelium-derived mediators also exert opposite effects on 
coagulation process: endothelial derived NO and PGI2 induce 
antithrombotic pathway inhibiting platelets aggregation, while other 
molecules, such as the Von Willebrand factor, and plasminogen activator 
inhibitor-1 which respectively promote platelets aggregation and inhibit 
fibrinolysis [54, 55]. 
However, the crucial player in the regulation vascular homeostasis is the 
Nitric Oxide, thus the disturbing of endothelium integrity and consequently 
NO release leads to endothelium dysfunction. 
1.5.3 eNOS and NO  
The role of endothelial cells in regulating vascular tone was first 
recognized with the observation that acetylcholine caused 
vasoconstriction when applied directly to de-endothelialized blood vessels, 
but induced vasodilatation in physiological vessels. The hypothesis that is 
still valid in the field is that the activation of the muscarinic receptor on 
endothelial cells by acetylcholine, induces the production of a relaxant 
molecule in endothelial cells, which after diffusing to subjacent vascular 
smooth muscle cells, activates the Guanylyl Cyclase and the subsequent 
vasorelaxing pathway. At the beginning this putative vasodilatory 
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compound was termed endothelial-derived relaxing factor, or EDRF. 
Then, with the discovery of nitroglycerin, the identity of EDRF passed to 
the Nitric Oxide (NO). Nitroglycerin is an organic nitrate commonly 
prescribed for angina pectoris. The effects of this molecule starts after its 
metabolization in the body in order to release NO which is responsible for 
the relaxation of vascular smooth muscle. 
NO, a free radical gas produced by Nitric Oxide Synthase (NOS) family of 
proteins, is a ubiquitous second messenger of the cardiovascular system 
involved in the regulation of different physiological process such as 
vasodilation, anti-coagulation, vascular remodeling and angiogenesis. 
Three different isoforms NOS have been discovered in mammalian: 1): 
neuronal NOS (nNOS or NOS-1), 2) inducible NOS (iNOS or NOS-2) 
activated in an inflammatory state and 3) endothelial NOS (eNOS or NOS-
3). In-vitro and in-vivo studies using NOS inhibitors, NO donors or using 
mice deficient in each of three mammalian isoforms have shown the 
importance of NO in the cardiovascular system. Indeed, the absence of all 
the three NOSs isoforms caused a drastically reduction of endothelium-
dependent vasorelaxation in murine arteries and also a increased the risk 
of cardiovascular diseases in these mice, including hypertension, cardiac 
hypertrophy, diastolic heart failure, arteriosclerosis and myocardial 
infarction leading to an earlier death of the animals [56]. This highlights 
the importance of Nitric Oxide in the regulation vascular physiological 
homeostasis.  
Placed in endothelial cells, eNOS is a multi-domain enzyme consisting of 
an N-terminal oxigenase domain and a C-terminal reductase domain with 
a CaM binding the region connecting the two domains. Several co-factors 
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are required for the synthesis of NO, namely tetrahydrobiopterin (BH4), 
Nicotinamide Adenine Dinuclotide Phosphate (NADPH), Flavin Adenine 
Dinucleotide (FAD) and Flavin Mononucleotide (FMN); the enzyme also 
contains binding sites for CaM and heme. The substrate necessary for the 
NO formation is L-arginine. eNOS, as all the three NOS isoforms, is 
synthesized as a monomer which needs to form dimmers in order to bind 
BH4 and the substrate L-arginine to catalyze NO production. When the 
complex Ca2+-CaM binds to the CaM binding domain in eNOS, the 
enzyme is activated and interacts with another monomer [57]. The zinc ion 
(Zn) is responsible for connecting the monomers at the heme group, 
which are resistant to the dimerization. This connection is further stabilize 
by BH4 [58]. Following the formation of this complex, an electron flux 
occurs from NADPH to FAD and FMN at the reductase domain towards 
the oxigenase domain where they are accepted by heme iron. At this 
point, eNOS can utilize the donated electron and molecular oxygen to 





Figure 1.7 eNOS and the biosynthesis of Nitric Oxide (NO) 
 
However, eNOS can also acts as a monomer, but in this condition it is 
only able to generate O2- instead of NO from their oxigenase domain. This 
condition is called un-coupling and causes an increase of the oxidative 




Figure 1.8 Uncoupled eNOS 
 
 
1.5.4 Cav-1 and eNOS interaction 
Vascular production of NO is predominantly regulated by eNOS activity 
specifically in endothelial cells. It is important to know that in basal 
condition, eNOS is expressed in the caveolae, cell-surface plasma 
membrane invaginations, which are present in several different cells 
including endothelial, adipocytes and muscles cells. These portions of the 
plasma membrane are marked by the presence of particular protein called 
caveolin (Cav-1, -2, -3), which are important in their formation. In 
caveolae, eNOS interacts with caveolins. Among the three isoforms of 
caveolin, caveolin-1 (Cav-1) principally interacts with and regulates eNOS 
by inhibiting its enzymatic activity [60, 61]. Several stimulus that are able 
to activate eNOS, serve to break down the bond between Cav-1 and the 
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enzyme. Indeed, different endogenous receptor-operated substances like 
acetylcholine, bradykinin and histamine acting on their own endothelial 
receptor, increase intracellular Ca2+ levels and by the formation Ca2+-
calmodulin complex calmodulin is directed to replace caveolin in its 
interaction with eNOS [62]. Thus eNOS binding calmodulin dissociates 
from Cav-1 and recovers its activity. At this point eNOS is a free enzyme 
in the cytosol of endothelial cells, which can be phosphorylated and 
activated to increase NO bioavailability. On the contrary, once Ca2+ 
concentrations return to basal levels, Cav-1 re-interacts with eNOS 
gaining again its place in caveolae (Figure 1.9). On this basis, Cav-1 
represents an important modulator of eNOS activity, and several studies 
have demonstrated how the interactions between Cav-1 and eNOS plays 
a role in vascular homeostasis regulation [63]. Experiments on mouse 
aorta rings mounted in insolated organ bath, have shown that a cell-
permeable peptide containing the region of caveolin-1 that binds to eNOS, 
was able to inhibit acetylcholine-induced vasodilation [64] while the 
completely absence of Cav-1 mice, allowed a significantly enhancement 
of the relaxation response induced by Acetylcholine, which was reversed 
by the inhibition of eNOS [65]. Since NO is also involved in vascular 
permeability, other experiments have been performed to evaluate the 
effect of Cav-1-eNOS interaction on edema. As expected, the injection of 
caveolin-1 scaffolding domain-containing peptide was able to ameliorate 
the edematous response in mice [64], while the loss of Cav-1 expression 
markedly increases the vascular permeability [66]. This hyper-permeability 
was reversed by eNOS inhibition, demonstrating the necessity of Cav-1 





Figure 1.9 Inhibitory effect of Cav-1 on eNOS activity 
 
1.5.5 Endothelial dysfunction 
Endothelial dysfunction is strictly correlated to the reduction of eNOS 
expression or activity, which leads to a decrease of NO bioavailability [67]. 
Oxidative stress is one of the major mechanisms involved in the alteration 
of endothelial cells function. In endothelial cells reactive oxigen species 
(ROS) are responsible to quench NO with formation of a peroxynitrite [68], 
which as cytotoxic oxidant is responsible for nitration and consequent lost 
of protein functions. Moreover, peroxynitrite leads to the reduction of the 
eNOS cofactor BH4 in BH2 causing the uncoupling eNOS process [53]. In 
this condition eNOS goes from its oxigenase function, which produce NO, 
to its reductase activity generating more ROS with consequent 
exacerbation of the oxidative stress.  
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eNOS activity in endothelial cells is also modulated by circulating factors 
like insulin [69]. This hormone is able to regulate vascular homeostasis 
with a vasodilator action exerted through the phosphoatidylinositol-3-
kinase (PI-3K)/AKT pathway-dependent eNOS activation [69]. Moreover 
insulin prevents ROS production and sustains eNOS activity by increasing 
BH4 [70], for these reason insulin resistance condition can be associated 
to a reduction of eNOS activity, NO bioavailability and following 
endothelial dysfunction. Oxidative excess is also linked to a pro-
inflammatory state of the vessel wall with an up-regulation of adhesion 
(VCAM-1 and ICAM-1) and chemotactic (MCP-1) molecules [71]. This 
inflammatory condition in vascular endothelial wall further reduces NO 
bioavailability and increase endothelial dysfunction. 
A relatively new and attractive mechanism that leads to reduced NO 
production is Asymmetric Dimethyl arginine (ADMA), an endogenous 
competitive inhibitor of eNOS that has been linked to endothelial 
dysfunction [72, 73]. ADMA is a product of protein turnover and is 
eliminated by excretion through the kidneys excretion or metabolism 
induced by dimethylarginine dimethylaminohydrolase (DDAH) to citrulline 
in hepatic cells. Patients suffering of chronic renal failure or hepatic 
dysfunction are characterized by high ADMA plasma levels which lead to 
a reduction of effective renal plasma flow and increased renovascular 
resistance and blood pressure, with further reduction of heart rate and 
cardiac output [74-76]. Moreover, plasma ADMA levels are also increased 
in patients affected by hypercholesterolemia and hypertension [77, 78] 
and can be also associated to increased cardiovascular risk factor, such 
as carotid intima-media thickness, concentric left ventricular hypertrophy 
and left ventricular dysfunction [79, 80]. However, it has been shown that 
50	  
	  
infusion of l-Arginine, the physiological substrate of eNOS and competitor 
of ADMA is able to normalize endothelial function and cardiovascular 
homeostasis [81].  
NO bioavailability is also reduced by the increase of homocysteine in 
endothelial cells responsible of the increase of the oxidative stress. 
Cardiovascular problems are associated to high levels of homocysteine in 
the blood since this molecule is responsible to increase plasma 
concentration of ADMA by inhibition of DDAH enzyme [81, 82]. 
Endothelium  and vascular function is also affect by the renin-angiotensin 
system (RAS).  Ang II also causes an increase of ROS by stimulating 
NADPH oxidase and promoting vascular inflammation [83]. These 
mechanisms are potentiated in the hypertensive conditions and represent 
the reason of the vascular dysfunction observed in these patients. Indeed, 
in hypertensive human patients, interruption of the renin-angiotensin 
system with angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers restores endothelial function [84]. 
Thus, all of these mechanisms are exacerbated in several pathological 
conditions such as hypertension, hypercholesterolemia with elevated 
oxidized LDL and low HDL-cholesterol, hypertriglyceridemia, 
atherosclerosis, renal and hepatic dysfunction, hyperglycemia and 
diabetes. Vascular dysfunction is the common factor in all these diseases 
and the therapeutic approach does not only include the treatment of the 
underlying disease which albeit only in some conditions, but it tries also to 




1.6 Diabetes as the main risk factors of cardiovascular 
diseases 
From the point of view of the cardiovascular medicine, diabetes is 
considered a cardiovascular disease. Several epidemiological and 
pathological data demonstrate that diabetes is an independent risk factor 
for CVDs, listed as the cause of death in 65% of people with diabetes. 
Diabetic patients often manifest large number of vascular occlusion 
compared with age-matched healthy people, which lead to an increase in 
the development of peripheral and cerebral-vascular diseases. The main 
consequence of the vascular occlusion is the ischemia. Ischemia is 
caused by a restriction of blood supply to tissues, which causes a 
reduction of oxygen and glucose for the cells and also an inadequate 
removal of metabolites. These processes are important in order to 
maintain cells alive, thus their alteration leads to a progressive cellular 
apoptosis. In order to compensate to this vascular the organism 
spontaneously develops new collateral blood vessel as a response to the 
vascular occlusion, trying to maintain the vitality of the tissue after the 
ischemia. This mechanism of neo-vascularization is called angiogenesis 
and is a common clinical observation that it results impaired in diabetic 
patients. The main growth factors involved in the generation of new blood 
vessels is the endothelium-derived VEGF. VEGF-mediated angiogenesis 
mechanism is active in ischemic tissue in order to compensate for the 
suppression of blood flow. Using the experimental model of Non Obese 
Diabetic (NOD) mice, which spontaneously develops a diabetic pathology 
similar to the human insulin dependent diabetes mellitus, Rivard and his 
colleagues in 1999 have shown that VEGF levels in ischemic tissues from 
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these mice are lower than the control. On the contrary, when NOD mice 
were injected with a replication-deficit adenovirus coding for murine 
VEGF, it has been demonstrated a significant improvement of blood flow 
and capillary density [85]. This confirms that diabetic condition, alters the 
VEGF-mediated angiogenesis pathway, leading to peripheral and central 
vascular occlusion and to a worsening of previously cardiovascular 
disease. 
The link between diabetes and vascular diseases is today well confirmed 
and involves the activation of different molecular mechanisms regulating 
the vascular homeostasis. Plasma glucose is responsible of the 
advanced-glycation end products (AGEs). AGEs are proteins or lipids that 
become glycated as a result of exposure to sugars. In the context of the 
vascular diseases, AGEs induce a crosslinking of collagen, which can 
cause vascular stiffening, and entrapment of low-density lipoprotein 
particles (LDL) in the artery walls. At this point, AGEs cause glycation and 
oxidation of LDL, which represent the major factors in the development of 
atherosclerosis [86]. Finally, AGEs can bind to Receptor for Advanced 
Glycation End-products (RAGE) causing oxidative stress as well as 
activation of inflammatory pathways in vascular [87]. Hyperglycemia 
causes an increase of intracellular AGEs formation and also increment the 
expression of RAGE exacerbating the vascular damage [88].  
Diabetes conditions is also associated increased levels of Free Fatty 
Acids (FFAs) which impair the endothelial function [89]. FFAs facilitate the 
activation of protein-kinase C (PKC) in the vasculature which is known to 
be associated with vascular alterations such as increase in permeability, 
contractility, extracellular matrix synthesis, cell growth and apoptosis, 
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angiogenesis, leukocyte adhesion and cytokines activation [90]. In 
particular in the pathological state of diabetes, PKC activates NADPH 
oxidase intensifying the oxidative stress [91]. Moreover, FFAs are also 
associated to AGEs formation and their interaction with RAGE [91]. 
Insulin resistance, which mainly characterized the diabetes, in particular 
type 2, is also responsible of the exacerbation of the vascular dysfunction 
in these patients. Insulin, acting on a tyrosine-kinase receptor in 
endothelial cells, is responsible to activate of eNOS/NO pathway which 
not only regulate the vasodilation but also inflammatory and thrombotic 
mechanism in the vascular wall. Moreover, insulin modulates eNOS 
activity by regulating the expression of BH4 [70]. Thus, absence of this 
signaling is responsible to further increase oxidative stress and endothelial 
impairment. Conversely, since insulin receptor (IR) is strongly associated 
to eNOS activation, it has been demonstrated that eNOS plays one of the 
major role in the regulation of insulin sensitivity due to the functions of NO 
in peripheral tissues [92]. Previous studies have also shown that mice 
lacking eNOS are more likely to develop insulin resistance, while 
modulation of eNOS phosphorylation affects insulin sensitivity [93]. In this 
context, is possible that eNOS phosphorylation could be a novel target for 
the treatment of insulin resistance helping also the rescue of the 
endothelial homeostasis. 
On the basis of this evidences, it appears obvious that NO bioavailability 
reduction is the common factor in all these altered vascular mechanism, 
and it is the mainly responsible of the endothelial dysfunction and CVD 
observed in diabetic patients. Salheen and colleagues confirmed these 
hypotheses when in 2015 they demonstrated that STZ-induced T1DM rats 
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show a reduction of basal production of NO in mesenteric artery 
compared to the healthy animals confirming by a reduced contractile 
response to the NOS inhibitor L-NNA [94]. 
Treatment with antidiabetic drugs reduces plasma glucose levels and 
increases insulin sensitivity being per se responsible to ameliorate 
vascular homeostasis. However lowering glucose levels is not sufficient to 
switch off intracellular pro-oxidant environment or completely restore the 
physiological vascular reactivity, indeed, vascular damage can perpetuate 
despite the achievement of improved glycemic control. In vitro 
experiments on cultured endothelial cells as well as in vivo studies on 
diabetic animals, have shown that after plasma glucose levels 
normalization, ROS and oxidative marker continued to increase vascular 
stress [95]. For this reason, new therapies are not only focused to lower 
hyperglycemia, but also to ameliorate vascular functions by directly acting 
on the endothelial molecular mechanisms responsible of the impairment of 
eNOS/NO pathway. In this regard, it has been show that a particular class 
of antidiabetic drugs, DPP-IV inhibitors, induce beneficial effect on 
vascular homeostasis regulation, beyond their capability to control glucose 
levels DPP-IV increasing incretinic system function.  
1.6.1 Incretin therapy and its incidence on vascular homeostasis 
regulation 
Incretin system acts by improving glucose metabolism through the 
upregulation of insulin secretion and suppression of glucagon release. 
Incretin analog and DPP-IV inhibitors potentiate the anti-hyperglycemic 
effect of incretin system, however it has been shown that beyond the 
regulation of blood glucose levels, these drugs have cardio-protective 
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actions, reduce atherosclerosis, and show beneficial vascular effect by 
improving the endothelial function in diabetic patients [96, 97]. 
In vitro studies on Human Umbilical Vein Endothelial Cells (HUVEC) have 
demonstrated that tinigliptin as a molecule belonging to DPP-IV family has 
antioxidant proprieties by reducing ROS concentration and oxidative 
stress in hyperglycemic conditions. This data has been also confirmed by 
clinical studies, which have evaluated the effect of teneligliptin and 
sitagliptin treatment in T2DM diabetic patients. Even if both two DPP-IV 
inhibitors induce the same effect on bloodstream control, teneligliptin also 
improves endothelial function by reducing the oxidative stress markers 
reactive oxygen metabolites (ROMs) and reduces the incidence of the 
chronic kidney disease, while sitagliptin doesn’t affect the vascular profile. 
Thus, the beneficial effect of tiniligliptin on vascular homeostasis is 
independent of blood-glucose lowering effect. [98]. 
In vitro studies have shown that the activity and expression of DPP-IV in 
endothelial cells appears to be increased when glucose levels are 
elevated [99]. For this reason the use of DPP-IV appears to be able to 
protect endothelial cells from the negative effects due to the 
hyperglycemic condition. It’s well know that endothelial cells show, not 
only DPP-IV enzyme, but also the GLP-1 receptor (GLP-1R) [100] and 
inhibition of DPP-IV induces a significantly increase of GLP-1 levels 
promoting its interaction with the GLP-1R expressed in endothelial cells. 
This interaction leads to an increase of cAMP in endothelial cells and a 
subsequently activation of KATP channel, regulating the vascular tone 
[101]. Since, NO is the mainly indicator of vascular endothelial function 
integrity and eNOS/NO pathway is impaired in diabetic condition, some 
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studies have focused their attention on the effect of incretin therapy on 
eNOS/NO signaling. Several experimental studies have confirmed that 
inhibitors of DPP-IV have favorable effects on systemic blood pressure 
and the control of vascular tone as well as endothelial growth and that 
these effects are not dependent on the activation of the GLP-1R [102, 
103]. Indeed, Shah et al have demonstrated that alogliptin, a DPP-IV 
inhibitor, induces vasodilatation in isolated vessels, which is not altered by 
GLP-1R antagonist [104]. STZ-induced diabetes in rats causes a 
progressive development of endothelium function impairment [105] related 
to a drastically decrease of NO production from ECs which has been 
confirmed by a reduction of Ach-induced vasorelaxation in isolated vessel 
and a reduction of basal contraction induced by NOS inhibitor Nω-nitro-L-
arginine (L-NNA) [94]. Additionally, in order to investigate the effect of 
diabetes on vascular smooth muscle relaxation it has been evaluated the 
Sodium Nitroprusside-induced vasorelaxation (SNP), as a NO donors, on 
isolated mesenteric arteries. The response to SNP in this study is similar 
in normal and diabetic rats, indicating that hyperglycemia only affects NO-
endothelium production but not its effect on VSMCs. However in this 
mirror of diabetes-induced vascular dysfunction, treatment with linagliptin 
improves Ach-induced relaxation in mesenteric arteries, probably by 
preventing the generation of superoxide anions via the antioxidant effect 
of linagliptin [106], reducing eNOS uncoupling and improving the 
bioavailability of NO in vascular endothelial cells [94]. Moreover, Salheen 
and colleagues demonstrate that basal contraction induced by NNA 
increases in mesenteric artery from diabetic rats treated with linagliptin 
compared the control, confirming that the DPP-IV inhibitor has an 
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important role in improving NO bioavailability and ameliorating endothelial 
vascular function [94]. 
 
1.7 Aim of the PhD Project 
Incretin and DPP-IV inhibitors therapies have been deeply correlated to an 
improvement of vascular endothelial function in diabetic condition. 
However, despite all the evidences, the molecular mechanism through 
which incretin and DPP-IV inhibitor improve NO bioavailability and 
ameliorate endothelial function is not yet clear. Before starting my PhD 
project, we have assessed some experiments to evaluate a possible cross 
talk between DPP-IV and the pathway L-Arginine/eNOS/NO using cells 
Human Embryonic Kidney (Hek), stably transfected with the enzyme 
eNOS (HEK-eNOS). Hyperglycaemic condition caused a drastically 
reduction of NOx production from the cells, as an indirect index of eNOS 
activity, both in basal and after the exogenous stimulation of Calcium 
ionophore. These first data were in accordance with an increase of Cav-1 
expression and a reduction of eNOS in Hek-eNOS cells. Incubation of the 
cells with linagliptin showed a greater increase of NOx production and a 
reduction of CAV-1 expression, while eNOS expression was not affected. 
These preliminary data were the first confirmation for us that linagliptin 
had a role in CAV-1/eNOS/NO signaling regulation. On this evidence the 
aim of my project is to clarify role of incretin hormones and DPP-IV 
inhibitors in the control of vascular homeostasis, both in physiological and 
physio-pathological focusing on the modulation of eNOS/CAV-1 as a 
possible molecular mechanism responsible for the beneficial vascular 





All animal procedures were performed according to the Declaration of 
Helsinki (European Union guidelines on use of animals in scientific 
experiments) and following ARRIVE guidelines and authorised by local 
animal care office (Centro Servizi Veterinari, Università degli Studi di 
Napoli “Federico II”). This work has been carried out using: NOD/Ltj and 
age-matched CD-1 control mice (Charles River, Calco, Italy). GLP-1R-/- 
mice and Guanilate Cyclase-α1 (GCα1-/-) mice has been also used and 
supplied by Boheringer Ingelheim (Ingelheim, Germany) and Prof. P. 
Brouckaert from the University of Ghent (Belgium), respectively. Mice 
were kept in an animal care facility under controlled temperature, humidity 
and light/dark cycle conditions, with food and water ad libitum. 
2.2 Reagents 
Calcium ionophore A23187, Trizma base, Trizma HCl, Sodium chloride 
(NaCl), Glycine, Methanol, Nonidet-40 (NP-40), cocktail of protease and 
phosphatase inhibitors, Sodium Ortovanodate (Na3VO4), TritonX, Sodium-
deoxycholate, Sodium Dodecyl Sulphate (SDS), Ammonium 
Peroxydisulfate (APS), Acrylamide, N N,N,N-Tetramethyl ethylenediamine 
(TEMED), 2-mercaptoethanol, EDTA, Luminol (a-8511), p-coumaric acid, 
Tween-20 and all the salts of Krebs solution were purchased from Sigma-
Aldrich (Italy, Milan). Antibodies Anti-caveolin-1, Anti-eNOS and Anti-
GAPDH were purchased from Santa Cruz respectively Biothecnology Inc 
(Santa Cruz, California, USA), from BD Biosciences and Sigma-Aldrich 
(Italy, Milan). All reagents for cell culture were purchased from Lonza. 
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Fluo-4 NW Calcium Assay Kit was purchased from Invitrogen, Carlsbad, 
California). The Linagliptin was kindly provided by Boehringer (Germany). 
2.3 Non Obese Diabetic (NOD) mice 
Not Obese Diabetic mice (NOD) are an experimental animal model 
characterized by a marked susceptibility to hyperglycemia leading to the 
development of a diabetic pathology similar to human type 1 diabetes, 
IDDM. Measuring once a week glycosuria levels these animals were 
classified into three groups, in relation to the severity of the diabetic 
pathology (Figure 9): 
• The NOD or NOD I, the animals at this stage not yet show signs of 
diabetic pathology and present levels of glycosuria less than 20 mg / 
dl (0 <gl <20 mg / dl); 
• NOD II, such a stage is reached at about the thirteenth week of age 
and of glycosuria levels are between 20 mg / dl and 500 mg / dl (20 
<gl <500 mg / dl); 
• NOD III, the animals, the twenty-second week of age, showing signs 
of a full-blown diabetic condition with urine glucose levels over 500 
mg / dl (gl> 500 mg / dl). 
 
 




NOD I: 0<glicosuria<20 mg/dl = low or null glycosuria 
NOD II: 20<glycosuria<500 mg/dl = high glycosuria 




        Figure2.1 Gradually increase of NOD glycosuria levels  
during diabetes development  
 
2.4 In-vivo treatment with Linagliptin in NOD/Ltj mice 
NOD mice are treated with vehicle or with linaglitin (Boehringer Ingelheim) 
at a dose of 1mg/kg/day by gavage, following two different protocols: 
Ø Preventive protocol: treatment with linagliptin occurs when the 
animals are considered still healthy, and continues until they reach 
the stage of NOD II and NOD III, monitoring glycosuria levels during 
the therapy 
Ø Therapeutic protocol: treatment occurs when animals start to show 
the symptoms of diabetes with glycosuria levels corresponding to 
stage II, and the administration of linagliptin continues to the 
stadium of NOD III. 
In both protocols, as a result of the treatment, the animals were sacrificed 
and the thoracic aorta was removed to evaluate asses molecular analysis 
and evaluate the vascular reactivity by ex-vivo studies in baby baths for 














2.5 Isolated organ bath studies  
2.5.1 Vascular tissue preparation 
Males NODI-III, CD-1, GLP-1 Knock Out (KO) and Guanilate Cyclase 
(GC) KO mice were used to evaluate the vascular reactivity on aorta and 
carotids vascular tissues. Mice were anaesthetized with enflurane (5%) 
and then killed in CO2 chamber (70%). Aorta and carotid vessels were 
rapidly harvested, and adherent connective and fat tissue were removed. 
Aorta rings of 1-1.5 mm length were cut and placed in organ baths 3.0 ml 
of volume, while carotids rings 3.0 mm length were mounted 5 ml volume 
chamber. Both the vascular rings were  filled with oxygenated (95% O2 - 
5% CO2) Krebs solution and kept at 37°C. Aorta and carotid rings were 
connected to an isometric transducer respectively 7006-Ugo Basile 
(Comerio, Italy) and DMT Wire Myograph, and changes in tension were 
continuously recorded with a computerized system (DataCApsule-17400, 
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Krebs solution was as follows (mM): 118 NaCl, 4.7 KCl, 1.2 MgCl2, 1.2 
KH2PO4, 2.5 CaCl2, 25 NaHCO3 and 10.1 glucose. The rings were 
initially stretched until a resting tension of 1.5 g was reached and then 
were allowed to equilibrate for at least 30 min; during this period the 
tension was adjusted, when necessary, to 1.5 g and the bath solution was 
periodically changed. In a separate set of experiments, aortic and carotid 
rings were denuded from endothelium by gently rubbing the internal 
surface of the vascular lumen. 
2.5.2 Experimental protocol 
In each set of experiments, rings were firstly challenged with 
phenylephrine (PE, 1µM) until the responses were reproducible. In order 
to verify the integrity of the endothelium, cumulative concentration-
response curves to Acetylcholine (Ach, 10nM – 30µM) were performed 
with 1µM PE pre-contracted rings. Rings not reaching a relaxation 
response of at least 75% were considered , while vessels reaching a 
vasodilatation less the 20% were considered endothelium-denuded. 
Ach and Isoprenaline (Iso) curves (10nM – 30µM) has been performed on 
aorta rings from NOD I, NOD II and NOD III mice in basal conditions and 
following the preventive and therapeutic treatment with Linagliptin 
1mg/Kg, to evaluate vessel’s vasodilatation response both endothelium 
dependent and independent respectively.  
Aorta and carotid rings from NOD III, CD-1, GLP-1 KO and GC KO mice 
were contracted with PE (1µM) and, once the plateau was reached, 
cumulative concentration-response curves to Linagliptin (LIN) and 
Sitagliptin (SIT) (100nM – 30µM) has been performed. Moreover, 
concentration-response curves of Linaglipton has been assessed on aortic 
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and carotid rings in presence or absence of endothelium, and after 
incubation with N5-(1-iminoethyl)-L-ornithine dihydrochloride, L-Nio (NOS 
inhibitors) 10µM for 15 minutes and 1H-[1,2,4]Oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ, GC inhibitor) 10µM for 15 minutes and on 
vessels denuded from endothelium. 
Krebs solution was used as the vehicle for all isolated organ bath 
experiments.  
2.6 Cell culture experiments in a normal and high-glucose 
environment 
Human Embryonic Kidney cells stabled transfected with eNOS (Hek-
eNOS cells) and Bovine Aortic Endothelial Cells (BAEC) were cultured in 
Dulbecco Modified Eagle’s Medium (DMEM) containing Fetal Bovine 
Serum 10%, HEPES (1M), Na-Piruvate (100mM), L-Glutamine (200mM), 
G418 and solution of Penicillin-Streptomycin (10.000 units of Penicillin 
and 10 mg Streptomic/ml). Cells at 80% of confluence were starved with 
Medium prepared without FBS. Hek-eNOS cells incubated with Linagliptin 
(0.1 – 10 – 100 nM for one hour and then treated for 2 hours with 25 mM 
D-glucose solution (Normal Glucose) or 50mM D-glucose solution (High 
Glucose). Immediately thereafter, cells were stimulated with Calcium 
Ionophore A23187 10µM for 30 minutes. Cells were then separated from 
the supernatant and utilized for western blot analysis (eNOS and Cav1 
expression) while the medium was collected and used for nitrite/nitrate 
(NOx) assay. The same protocol was utilized for BAEC increasing the 






2.7 Western Blot analysis 
Hek-eNOS cells and aorta vessels, harvested from NOD III after the 
respective treatments described above, were individually homogenized in 
modified RIPA buffer (Tris HCl 50 mM, pH 7.4, triton 1%, Na-deoxycholate 
0.25%, NaCl 150 mM, EDTA 1 mM, phenylmethanesulphonylfluoride 1 
mM, aprotinin 10 µg/ml, leupeptin 20 mM, NaF 50 mM) using a polytron 
homogenizer (two cycles of 10 sec at maximum speed) on ice. After 
centrifugation at 12,000 rpm for 15 min, protein concentration was 
determined by Bradford assay using BSA as standard (Bio-Rad 
Laboratories, Milan, Italy). Denatured proteins of each sample were 
separated on 10% SDS/PAGE and transferred to a PVDF membrane. 
Membranes were blocked in PBS-tween 20 (0.1%, v/v) containing 3% non 
fat dry milk for 1 hour at room temperature, and then incubated with anti-
eNOS (1:500), anti Cav-1 (1∶1000) or anti-GAPDH (1∶1000) overnight at 
4°C. The filters were washed with PBS-tween 20 (0.1%, v/v) extensively 
for 30 min, before incubation, for 2 hours at 4°C, with the secondary 
antibody (1∶5000) conjugated with horseradish peroxidase antimouse IgG. 
The membranes were then washed and immunoreactive bands were 
visualized using an Enhanced Chemiluminescence Substrate (ECL; 
Amersham Pharmacia Biotech, San Diego, CA, USA). Images were 
obtained using ImageQuant-400 (GE Healthcare, Chicago, IL, USA). The 
housekeeping protein GAPDH (1:5000, Sigma-Aldrich, Milan, Italy) was 







2.8 NOx Assay 
NOx Assay was performed according to Thomsen [107], with modification. 
Cultured Medium of Hek-eNOS and BAEC cells were collected and 
incubated for 75 minutes with acid washed (0.24M HCl) cadmium powder 
(Sigma Aldrich) to reduce nitrate in nitrite. After the incubation period, the 
samples were centrifuged. The obtained supernatants were then used to 
quantify NOx levels trough a spetto-fluorometric assay with the following 
wavelengths: excitation 365 λ and emission 450 λ. NOx levels in each 
samples were interpolated trough a standard curve of NaNO2 (50-
2000nM).  
2.9 Immunoprecipitation study 
Immunoprecipitation analysis was performed on BAEC (300µg total 
protein) Lysates were pre-cleared by incubating with protein A/G-Agarose 
(SantaCruz Biotechnology, Hidelberg, Germany) for 1 hour at 4°C and the 
incubated under agitation for 18 hours at 4°C with the relevant antibodies. 
Subsequetly, samples were incubated for 1 hour at 4°C with fresh beads, 
washed in PBS and then the antigen-antibody complexes were collected 
by centrifugation. SDS-PAGE and immunoblotting were performed as 
described above, and mouse monoclonal anti-eNOS (1:500, BD-
Trasduction Laboratories, Milano, Italy) and rabbit polyclonal anti-
caveolin-1 (CAV-1, 1:1000, SantaCruz Biotechnology) were used as 
primary antibodies.   
2.10 Measurement of intracellular Ca2+ 
Changes in the intracellular Ca2+ concentration were measured in BAEC 
using Fluo-4 NW Calcium Assay Kit (Molecular probes, Invitrogen, 
Carlsbad, California).  
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BAEC cells were plated in 96-well microplates (polyd-lysine-coated plates) 
to near confluence in a concentration of 20000 cells/well. Dye solution 
Fluo-4, composed by Fluo-4 NW dye mix and Probenenecid) was 
prepared following the manufacturer’s instructions. After cultured 
overnight cells with DMEM, they were washed with PBS and incubated 
with 100µl of the dye solution Fluo-4 at 37°C for 30 minutes, and then at 
room temperature for an additional 30 minutes. At the end of incubation, 
Fluo-4 solution has been replaced with a stabilizing solution pH 7.4 
composed as follow: Hepes 20nM,NaCl 120mM, KCl 2 mM. CaCl2 2mM, 
MgCl2*H2O 1mM and Glucose 5mM. Ca2+ concentration were measure in 
basal conditions and after stimulation of Linagliptin 1-10-100nM and 
Bradykinin and A23187 were used as positive control. Fluorescence 
(excitation 485 nm, emission 525 nm) was measured for 3 minutes in a 
microplate fluorometer (Promega, Madison, WI, USA). Data were 
compared with BAEC stimulated with vehicle and expressed as relative 
fluorescence.  
2.11 Statistical analysis 
All data were expressed as mean ± standard error of the mean (s.e.m.). 
Statistical analysis was performed using one-way analysis of variance 
(ANOVA), followed by Dunnet’s post-test, or two-way ANOVA followed by 
Bonferroni’s post-test (GraphPad software, San Diego, CA, USA). 







3.1 Diabetic conditions alter Acetylcholine and Isoprenaline-induced 
vascular homeostasis regulation 
The development of T1DM in NOD mice is associated with a progressive 
impairment of vascular relaxation. Indeed, in aortic rings Ach induced a 
concentration dependent vasodilatation, which reached a maximum value 
(Emax) of 74.69±3.56% relaxation at a concentration of 30µM, while this 
effect was significantly reduced in NOD II and NOD III  (Figure 3.1, A-B). 
The same results have been also observed with Iso. Diabetic conditions 











      



















       




















        



















       



















        
Figure 3.1(A-B) Ach-induced vasodilation in NOD II and NOD IIImice compared to control 
mice (EC50 Ach: 248,7nM vs 65,4nM and 93,4nM, CD1 vs NOD II and III, ***p <0.001, n = 4). 
(C-D) Vasodilation curve of Isoprenaline incontrol, NODII and NOD III mice (EC50 Iso: 
1,166µM vs 64, 2nm and 279,8nM, CD1 vs. NOD II and III, ***p <0.001 n = 4)  
 
3.2 In-vivo treatment with Linagliptin ameliorates Ach and Iso-
vascular response in diabetic mice without affecting the 
development of diabetes 
NOD II and NOD III mice in-vivo treated with Linagliptin following both 
preventive (NOD I NOD III) and therapeutic  





vasorelaxant effect, compared with mice were as been injected only the 
vehicle, even if the vasodilatation is not completely restored to the 
physiological condition (Figure 3.2, A-F). Moreover, glycosuria levels 
measurement during both preventive and therapeutic treatment with 
Linagliptin reveals that the vascular effect is totally. This effect is totally 
independent from the intrinsic action of the drugs in controlling blood 
glucose levels, since the development of the diabetic pathology in NOD 
mice in not reduced. (Figure 3.2, G-H) 
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Figure 3.2 Ach-induced vasodilatation in (A) NOD II and (B) NOD III mice after preventive 
treatment with Linagliptin compared to mice terated with vehicle (EC50 Ach NOD II: 149nM vs 
65,4nM, Lin 1mg/ml vs vehicle, °°°p<0.001, n=20; NOD III: 128nM vs 93,4nM, Lin 1 mg/ml vs 
vehicle, °°°p<0.001, n=12) (C-D): Vasodilatation curve of Isoprenaline in  NODII and NOD III 
mice respectively after preventive treatment (EC50 Iso NOD II: 69,4nM vs 64,2nM, Lin 1 mg/ml 
vs vehicle, ***p<0.001, n=19; NOD III: 592,4nM vs 279,8nM, Lin 1 mg/ml vs vehicle, 
***p<0.001, n=12). (E) Ach and (F) Iso-induced vasodilatation in NOD III mice after therapeutic 
treatment with Linagliptin ((EC50 Ach: 359nM vs 46,96nM, Lin 1mg/ml vs vehicle, *** p<0.001, 
n=5; EC50 Iso: 1,255µM vs 433,6nM, Lin 1 mg/ml vs vehicle, ***p<0.001, n=4). Glycosuria 






















3.3 Treatment with Linagliptin increases eNOS and reduces Cav1 
expression in NOD III mice 
Since Ach and Iso-induced vasodilation involve Nitric Oxide (NO) release, 
which is the main endothelium-derived vasorelaxing mediator, we have 
evaluated the expression on eNOS and its plasma membrane protein 
regulator CAV-1 on homogenized aorta from Linagliptin treated NOD III. 
Several studies have previously shown that in diabetic condition the 
impaired endothelium-dependent vasodilatation is associated to an 
increased expression of CAV-1 [108]. Following this evidence, we have 
evaluated the effect of Linagliptin treatment on CAV-1 and eNOS 
expression in aorta harvested from NOD III mice. Linagliptin, in both 
preventive and therapeutic regimen, modulates the expression of these 
two proteins towards to a more active state. Indeed, in aorta homogenates 
eNOS analysis shows a trend of enhanced expression following 
Linagliptin treatment, associated to a reduction of CAV-1 (Figure 3.3, A-B) 
These data, taken together, suggest that Linagliptin exerts a positive 











                         








































































Figure 3.3 (A-B) Western blot images of eNOS and CAV-1 performed on aorta  homogenates 
harvested from NOD III mice after treatment with vehicle and Linagliptin. (A) eNOS expression 
in homogenized aorta from NOD III mice treated with Linagliptin following preventive  (OD mm2 
eNOS/GAPDH: 0.77 ± 0.045 vs 1.198 ± 0.35 n=3) and therapeutic (OD mm2 eNOS/GAPDH: 
0.77 ± 0.045 vs 1.59 ± 0.31 *p<0.1 n=3) regimen. (B) Effect of Linagliptin treatment on CAV-1 
expression in NOD III aorta (Preventive treatment, OD mm2 Cav1/GAPDH: 1.23 ± 0.21 vs 0.84 
± 0.15, NOD III + vehicle vs NOD III + Lin, n=3; Therapeutic treatment, OD mm2 
Cav1/GAPDH: 1.23 ± 0.21 vs 0.63 ± 0.23, NOD III + vehicle vs NOD III +  Lin, n=3) 
	  
3.4 Linagliptin promotes eNOS activation and increases NO 
production  in vitro model of endothelial cells 
Starting with Human Embryonic Kidney cells stably transfected with 
endothelial enzyme eNOS, we have demonstrated that high glucose 
environment affects eNOS activity ( reduction of NO production) in this in-
vitro model. Indeed, in normal glucose environment, upon calcium 
ionophore A-23187 challenge, HEK-293 produces about 3.6 ± 0.30 nM of 



























significantly reduced by 40% while Linagliptin treatment (1-100nM) in high 
glucose environment restores the physiological pattern observed in 
normal glucose environment (Figure 3.4, A). Indeed, Linagliptin gradually 
increases NOx levels in a concentration-dependent manner, with a 
maximal effect at 100nM. These data are supported by Western Blot 
analysis which prove that reduction of NO content in high glucose 
environment is associated to an increase of CAV-1 expression compared 
to control condition. However, after treatment with Linagliptin 100 nM, 
homogenized Hek-eNOS cells show a reduction of CAV-1 with 
consequent eNOS activation and enhanced NO levels in cell’s medium 
(Figure 3.4, B). 
Overall these data indicate eNOS/NO signaling as the molecular target for 
the beneficial action of Linagliptin on endothelial function.	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Figure 3.4 (A) Effect of Linagliptin (0.1-1-10 nM) on Ca2+ ionophore A23187-induced NOx 
levelsin Hek-293-eNOS cells in Normoglycaemic (NG) and Hyperglacaemic (HG) environment 
(NOx concentration: 3.61nM ±0.30 vs 2.15nM ±0.17 as vehicle in NG vs vehicle in HG, 
**p<0.01, n=8; 2.15nM ±0.17 vs 3.96nM ±0.69, HG vs HG+Lin 100nM, °°p<0.01, n=3). (B-C) 
Western Blot images of eNOS and CAV-1 protein in Hek-293-eNOS cells in the HG conditions 
after treatment with Linagliptin 100nM. Data are compared with Hek-293-eNOS cells in the NG 
or HG condition treated with vehicle (B: OD mm2 eNOS/GAPDH, 5.54 ±0.25 vs 2.014 ±0.33 vs 
2.56 ±0.77 as NG vs HG vs HG+Lin 100nM, ***p<0.001 n3; C: OD mm2 Cav1/GAPDH, 1.98 
±0.3 vs 6.06 ±1.9 as NG vs HG, *p<0.1 n=3; 6.06±1.9 vs 2.52±1.2, HG vs HG+Lin 100nM, 
°p<0.1 n=3). 
 
3.5 Linagliptin induces vasodilation involving eNOS/NO/cGMP 
pathway 
Even if several previous studies have already demonstrated that DPP-IV 
inhibitor are also considered vasorelaxant agent, we have better 
characterized the vasodilating proprieties of Linagliptin on aorta and 






vasodilation in both vascular tissues in a concentration-dependent manner 
(100 nM – 10µM), compared the vehicle (DMSO) (Figure 3.5 A. E). This 
effect is not associated to inhibition of DPP-IV, since Sitagliptin, 
associated to the same class of drugs, has a less vascular activity (Figure 
3.5 A, E). 
However, in endothelium denuded vascular rings Linagliptin loses its 
vasorelaxing proprieties indentifying the endothelium as the main player in 
its vasodilatation (Figure 3.5 B, F). In this context, NO represent the most 
important mediator released from the endothelium and involved in 
endothelium homeostasis regulation. Moreover, our previous studies have 
shown that Linagliptin treatment ameliorates endothelium dependent 
vasorelaxation in diabetic mice and in-vitro analysis have proved that it 
regulates eNOS/NO activity. Therefore in order to better understand the 
molecular mechanism below Linagliptin action, we have evaluated 
Linagliptin vascular effect in presence of specific inhibitors of 
eNOS/NO/cGMP pathway. Incubation of aortic and carotid rings with L-
NIO, a selective eNOS inhibitor, significantly reduces Linagliptin-induced 
vasorelaxation (Figure 3.5 C, G). Similarly, incubation with ODQ, inhibitor 
of NO-dependent sGC activity, significantly inhibits linagliptin-induced 
vasorelaxation (Figure 3.5 D, H), even at a major extent compared with 
the effect achieved with  L-NIO, thus confirming a key role for NO/cGMP 
in linagliptin-induced vasorelaxation. 
 
       
76	  
	  












































































    
             
 
 
















































































            
Figure 3.5 (A) Linagliptin and Sitagliptin-induced vasodilatation in aortic rings from CD-1 
(%Emax:18.8 ±2.53%vs 56.66 ±3.72% as vehicle vs LIN, ***p<0.001, n=10; 56.66 ±3.72% vs 
30 ±4.2% as LIN vs SIT, ***p<0.01 n=6). Vasodilatation induced by Lianagliptin (B) in absence 
of endothelium, after incubation of (C) L-NIO and (D) ODQ in aorta tissue(Emax and EC50: 
56.66 ±3.72% vs 36.66 ±5.88% as LIN vs LIN w/o endothelium, ***p<0.001, n=10; vs 30.16 
±6.7% as LIN vs LIN +L.NIO, ***p<0.001, n=6; vs 17 ±5.66% as LIN vs LIN +ODQ, p<0.001, 
n=4). (E) Vascular effect of Linagliptin and Sitagliptin in isolated carotid rings compared the 
vehicle. Liangliptin induced vasodilatation in (F) endothelium denuded carotid rings, and in 
presence of (G) L-NIO and (H) ODQ (%Emax:6 ±1.15% vs 45 ±7.19% as vehicle vs LIN, 
***p<0.001, n=5; 45 ±7.19 % vs 15 ±4.41% as LIN vs SIT, ***p<0.01 n=5; vs 16 ±1.95% as LIN 
vs LIN w/o end, ***p<0.001, n=4; vs 78.14 ±1.94% as LIN vs LIN + L-NIO, p<0.001, n=5; vs 12 




















3.6 Endothelium dynsfunction in diabetic mice impairs Linagliptin-
induced vasodilatation 
The same panel of experiments described above have been performed 
also on aorta and carotid vessels harvested from NOD III mice with severe 
glycosuria.  As Figure 3.6 A shows, Linagliptin induces vasodilatation in 
NOD III mice, although to a minor extent compared to control mice. 
Similarly to what observed in control mice, Sitagliptin- induced 
vasorelaxation is lower compared to Linagliptin in NODIII mice (Figure 3.6 
B). When aortic rings are incubated with L-NIO, Linagliptin-induced 
vasodilatation results significantly reduced (Figure 3.6 C) confirming the 
involvement of NO release in Linagliptin vasodilating action. Conversely, 
in carotid vascular district, Linaglitpin-induced vasodilatation is not 
different from control mice (Figure 3.6 D), but also in this artery L-NIO 
significantly inhibits linagliptin-induced vasorelaxation and sitagliptin-












































          


































        


































Figure 3.6 (A) Concentration-response curve of LIN (0.1-10µM) on isolated aorta rings 
harvested from NOD III compared to control mice (%Emax: 90.27 ±2.94% 53.46 ±5.79% as 
CD1 vs NOD III, ***p<0.001, n=11). (B) Sitagliptin induced vasodilation and (C) L-NIO effect 
on Linagliptin vasodilating action in NOD III aorta (%Emax: 53.46 ±5.79% vs 12.66 ±4.41% as 
LIN vs SIT, ***p<0.001, n=4; vs 33.75 ±3.03% as LIN vs LIN+L-NIO, ***p<0.001, n=4). (D) 
Linagliptin, (E) Sitagliptin on NOD III carotid rings, and (F) effect of L-NIO incubation on 
Linagliptin vasodilation in this vascular district (%Emax: 81.8 ±9.07% 72.7 ±7.34% as CD1 vs 






NOD III, n=5; 72.7 ±7.34% vs 21.33 ±2.9% as LIN vs SIT, ***p<0.001, n=3; vs 12.5 ±4.8% as 
LIN vs LIN+L-NIO, ***p<0.001, n=4)  
                              
3.7 Linagliptin-induced vasodilatation does not involve GLP-1 
receptor (GLP-1R) activation 
It’s well know that endothelial cells show, not only DPP-IV enzyme, but 
also the GLP-1 receptor (GLP-1R) [100] and inhibition of DPP-IV induces 
a significantly increase of GLP-1 levels promoting its interaction with the 
GLP-1R expressed in endothelial cells. This interaction leads to an 
increase of cAMP in endothelial cells and a subsequently activation of 
KATP channel, regulating the vascular tone [101]. Since Linagliptin acts as 
DPP-IV inhibitors and prolongs GLP-1 circulating levels and its vascular 
activity, we performed in-vitro experiments in aorta rings harvested from 
GLP1-R -/- mice in order to prove that Linagliptin-induces vasodilatation 
independently from GLP1R activation. 
The same experimental protocol used for the in vitro study described 
above has been performed on GLP-1R-/- mice and on their respective 
littermates. Our results show that linagliptin-induced vasodilatation is 
completely preserved in aortic rings of GLP-1R-/- (Figure 3.7 A, B) and  
incubation with L-NIO and ODQ further reduces the vascular effect (Figure 
3.7 C, D). These evidences mask an directly action of Linagliptin on 
vascular homeostasis regulation which is completely independent from 











































































           
Figure 3.7 (A) Linagliptin and (B) Sitagliptin-induced vasodilatation on aorta rings from GLP-
1R-/- and their littermates (Emax %:50.750 ±6.762% vs 53.750  ±9.214% as LIN in WT vs GLP-
1R-/-, n=4; 18 ±8% vs 11 ±1% as SIT in WT vs GLP-1R-/-, n=4). Linaglitpin-induced 
vasodilatation in presence of (C) L-NIO and (D) ODQ (Emax%: 50.750 ±6.762% vs 26 ±8.8% as 
LIN WT vs WT + L-Nio, ***p<0.001, n=4; 53.750 ±9.214% vs 32 ±13% as GLP-1R-/- vs GLP-
1R-/- + L-Nio, °°p<0.01, n=4; 50.750 ±6.762% vs 25.25 ±7.18% as LIN WT vs WT + ODQ, 
***p<0.001, n=4; 53.750 ±9.214% vs 16 ±6.028% as GLP-1R-/- vs GLP-1R-/- + L-Nio, 








3.8 Absence of Guanilate cyclase abrogates Linagliptin-induced 
vasodilation 
In order to confirm that the direct effect of Linagliptin involves the 
eNOS/NO/cGMP pathway, we performed the cumulative cpncentration-
response curve of the DPP-IV inhibitor on both aorta and carotid rings 
harvested from sGC-/- mice, where the Guanilate Cyclase enzyme 
responsible of cGMP production is absent. In this murine model, 
Linagliptin-induced vasodilatation is completely abrogated confirming the 
involvement of NO and its downstream pathway in the vasodilating action 
of Linagliptin (Figure 3.8). 
 



































Figure 3.8 Concentration-response curve of Linagliptin in (A) aortic and (B) carotid rings 
harvested from sGC-/- mice compared to WT (Emax%:47.750 ±4.7%vs 9.5 ±2.10% as aorta WT 

















3.9 Linagliptin interferes with eNOS/CAV-1 complex independently 
from Ca2+ 
Results obtained above show that eNOS/NO signalling activation is 
significantly responsible in Linagliptin-induced vasodilation. Since Ca2+ 
intracellular concentration and Cav-1 represent the main regulator of 
eNOS activation, we performed experiment on BAEC cells, which 
spontaeously express eNOS. Firstly, following the same experimental 
protol used for Hek-293 eNOS cells indirectly quantified eNOS activity 
after treatment with Linagliptin in HG enviroment throught the 
measurement of NO levels. As happen for Hek-293-eNOS cells, high 
glucose environment causes a significantly reduction of medium NO 
levels, compared the normoglycaemic control. However, Linagliptin 
treatment with 100 nM significantly increases NO production in the 
medium, restoring the physiological pattern showed in normoglicaemia 
(Figure 3.9 A). Subsequently, using FLUO-4 AM assay we measured the 
Ca2+ intracellular levels of BAEC after Linagliptin treatment. Compared to 
positive control such as bradykinin or A24187 stimulation, Linagliptin does 
not induce Ca2+ levels increase (Figure 3.9 B). This findings affirme that 
eNOS/NO signaling activation is not dependent on an increase of calcium 
flux inside the cells. immunoprecipitation analysis between eNOS and its 
negative regulator protein Cav-1, show that in untreated BAEC cells a 
protein band immunoreactive to anti-eNOS antibody can be detected in 
the Cav-1 immunoprecipitation. However, treatment with Linagliptin (10 
and 100 nM) significantly reduces the eNOS co-immunoprecipitation with 
Cav-1 in a concentration dependent manner. This last result prove that 
Linagliptin control eNOS/NO signaling by interfering with eNOS/Cav-1 
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Figure 3.9. (A)Effect of Linagliptin (0.1-10.100 nM) on Ca2+ ionophpre A23187-induced NOx 
levels in BAEC placed in normo and hyperglicemic condition (NOx concentration: 1.249 µM 
±153.1 vs 764 nM ±78.43 as vehicle in NG vs vehicle in HG, *p<0.1, n=11; 764.6 nM ±78.43 
vs 1.204 M ±143 as vehicle in HG vs Lin 100nM in HG, °p<0.1, n=15). (B) Effect of Linagliptin 
(0.1-10.100 nM) on intracellular Ca2+ influx in BAEC n=3. Data are compared with BAEC 
stimulated with vehicle or with BK and Ca2+ Ionophore A23187 as positive control. (C) 
Immunoprecipitation (IP) of Cav-1 followed Western Blot analysis of eNOS and CAV-1 in 
































DPP-IV inhibitors represent a class of antidiabetic drugs,  which have 
been shown to improved the vascular function independently to their 
ability in controlling blood glucose levels. Hyperglycemic condition 
damages endothelium layer with consequent impairment of eNOS/NO-
mediated control on vessels homeostasis leading to vascular dysfunction. 
Several recent studies have already proved that DPP-IV-inhibitors-
treatment in STZ-induced diabetic rats ameliorates endothelial functions 
increasing Ach-induced vasodilatation in the harvested mesenteric 
arteries. Even if this observation could be associated to the DPP-IV-
mediated reduction of blood glucose levels and consequent decrease of 
endothelium damage, other articles in this field have demonstrated DPP-
IV inhibitors induce vasodilatation in isolated rat mesenteric artery. Thus, 
these drugs are directly involved in vascular homeostasis regulation, but it 
has been not yet clarified the molecular mechanism through which DPP-IV 
inhibitors mediate their beneficial vascular effect.  
In our study we have firstly selected a T1DM animal model, as the NOD 
mice to investigate the vascular effect of DPP-IV inhibitors. DPP-IV are 
commonly used for T2DM treatment, thus, since NOD mice spontaneously 
develop an autoimmune diabetes with a remarkable analogy to human 
T1DM, this approach allowed us to separate the antidiabetic effect of 
these drugs from their vascular beneficial effect minimizing the 
confoundable variable that reduction of glycaemia per se has a beneficial 
vascular effect. The number of DPP-IV inhibitors used in therapy is high 
and it is still increased. Our hypothesis on the involvement of DPP-IV 
inhibitors in vascular homeostasis control has been developed using 
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Linagliptin, a DPP-IV inhibitors introduced on 2010 in the T2DM therapy. 
Isolated aorta and carotid harvested from NOD mice show a drastically 
reduction of both Acetylcholine and Isoprenaline-induced vasodilatation, 
associating the development diabetic pathology with an impairment of 
eNOS/NO/sGC vascular pathway activation. However, in-vivo treatment 
with Linagliptin increases NO-dependent vasodilatation, independently 
from the development of diabetes, indeed, the spontaneous increase of 
glycosuria levels in NOD mice are not affected during the all treatment. 
Subsequently, in-vitro experiments prove that Linagliptin has strong 
vasorelaxing proprieties, which have been assessed on two different 
vascular districts, aorta and carotid vessels, in both healthy and diabetic 
conditions. Structurally, Linagliptin is a non-peptidomimetic molecule, and 
it can be distinguished from other DPP-IV inhibitor, as Sitagliptin 
characterized by a peptidomimetic structure. In healthy mice, 
vasodilatation induced by Sitagliptin is less than a half compared to 
Linagliptin, proving that the vascular effect observed cannot be 
generalized to all the class of DPP-IV inhibitors.  
The integrity of endothelium function is an important requisite for 
Linagliptin-induced vasodilatation. Diabetic conditions, which are known to 
be associated to endothelial dysfunction, significantly reduce and this 
reduction became more marked with the worsening of the disease (NOD I 
-> NOD II  -> NOD III). Moreover, in aorta and carotid vessels from 
diabetic and healthy mice inhibition of eNOS as well as sGC activity with 
specific molecular blockers leads to a significantly reduction of Linagliptin-
mediated vasodilatation, sustaining the hypothesis that vasodilation 
involved eNOS/NO/sGC pathway activation, which is further confirmed by 
the evidence that in aortic and carotid rings from sGCα1-/- Linagliptin-
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mediated vasodilation is strongly impaired. Moreover, our findings 
demonstrate that this effect is completely independent from the inhibition 
of DPP-IV enzyme since we have also proved that Linagliptin induced 
vasodilatation is almost absent in GLP-1R-/- mice isolated aorta.  
The hypothesis that DPP-IV inhibitors, in particular Linagliptin, have an 
important role in the regulation of eNOS/NO vascular signaling activation 
is supported by previous studies by Salheen et al who have demonstrated 
that basal contraction induced by NNA as eNOS inhibitor resulted 
increased in mesenteric artery from STZ-induced diabetic rats treated with 
linagliptin compared the control, confirming that the DPP-IV inhibitor has 
an important role in improving NO bioavailability and ameliorating 
endothelial vascular [94]. However, the mechanism underlying this 
beneficial interaction still needs to be clarified, and for this reason going 
forward our project and supporting our hypothesis of connection between 
Linagliptin and eNOS/NO activation, we have investigated the possibility 
that Linagliptin could interact with eNOS-Cav-1 complex. Since in 
endothelial cells Cav-1 acts as negative membrane protein modulator of 
eNOS activity, variation on its expression could easily be responsible for 
changes in eNOS activity modulation. Moreover, endothelium damage 
due to diabetic pathology could also affects eNOS-Cav-1 complex altering 
NO bioavailability [108]. Indeed, in a separate set of in-vitro experiments 
we have collected aorta tissue harvested from NOD III mice after 
treatment with vehicle and Linagliptin in order to observe variations in 
eNOS and Cav-1 expression.  Molecular analysis has shown that 
Linagliptin treatment participates in an up-regulation of eNOS activity and 
simultaneous decrease of Cav-1 expression, suggesting an increase of 
eNOS activity following the therapy. Based on this results we then focused 
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our attention on the effect of Linagliptin in a particular cellular in-vitro 
model of hyperglycemia. Firstly, we used Hek-293 cells transfected with 
eNOS, placed in a normo- and hyper-glycemic (NG and HG) conditions to 
mimic the physiological diabetic condition. Measurement of NOx levels in 
the cell medium have reported that, hyperglycemic condition drastically 
reduces the amount of NOx produced by cells levels, confirming all the 
previous ex-vivo vascular studies which demonstrated that the diabetic 
condition impairs eNOS/NO bioavailability. Moreover, these results are 
associated to a drastically increase of Cav-1 expression coupled with 
eNOS down-regulation showing a pattern which support the reduction of 
NO levels. However, in the hyperglycemic environment, Linagliptin 
treatment restores Cav-1 expression to levels observed in the 
normoglycemic conditions thus causes a simultaneous increase of NO 
bioavailability. This kind of pattern has been also confirmed in cells where 
eNOS enzyme is constitutively expressed, in order to better mimic the 
physiological condition. BAEC cells have been used for this purpose, and 
the same previous in-vitro experiments confirmed that Linagliptin 
promotes eNOS activity in high glucose environment increasing NO 
levels.  
At this point, we have developed the hypothesis that eNOS-Cav-1 
complex disruption represents the main molecular event responsible for 
the beneficial vascular effect induced by Linagliptin. Thus, we have 
addressed our attention to understand how the DPP-IV inhibitor interacts 
and regulates this endothelial complex. It is well known that one of the 
mechanism regulating eNOS-Cav-1 interaction is the increase of Ca2+ 
intracellular levels which leads to Ca2+-calmodulin complex and break of 
eNOS-Cav-1 binding. Thus, we pointed out the hypothesis that Linagliptin 
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might interact with plasma membrane or intracellular endothelial 
structures (i.e. membrane receptor or channel for ions cellular 
movements) acting as a calcium-mobilizing factor which increases eNOS 
activity by promoting the affinity of calmodulin to the enzyme and breaking 
the inhibitory interaction of Cav-1. However, this hypothesis has been 
ruled out by the Fluo-4 in-vitro experiments performed on BAEC cells. 
Indeed, it has been clearly shown that Linagliptin is not a calcium-
mobilizing agonist because has been not highlighted significant rise in 
intracellular calcium levels after stimulation with the molecule. The second 
possibility that we have considered is that Linagliptin directly interacts with 
the eNOS-Cav-1 complex. To assess this hypothesis we have performed 
Cav-1/eNOS immunoprecipitation study in BAEC cells previously treated 
with vehicle or with Linagliptin. Our results show that Linagliptin 
molecularly interacts with Cav-1 causing the break of eNOS-Cav-1 
complex and making the enzyme free to acts and increase the NO 
bioavailability. Thus, these last confirm the involvement of Linagliptin in 
eNOS/NO signaling regulation, sustaining that the pattern 
Linagliptin/eNOS/Cav-1 is the main event responsible of the vascular 
beneficial effect of Linagliptin in diabetic patients. 
Our findings conclude that in the pathological condition of hyperglycemia, 
where vascular homeostasis results impaired, Linagliptin induces a 
beneficial effect, without affecting hyperglycemia development. Moreover, 
this effect neither depends on its intrinsic propriety as inhibitor of DPP-IV 
neither on the increase of GLP-1 produced, while it is due to a direct 
interaction of Linagliptin on eNOS/Cav-1 complex. In the context of 
diabetic condition where impaired eNOS/NO pathway leads to vascular 
dysfunction, Linagliptin is able to replace eNOS from binding the negative 
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regulator Cav-1. This interaction improves eNOS activity and restores the 
NO bioavailability. Linagliptin is a drug already used in the therapeutic 
treatment in T2DM, nevertheless its protective role in vascular dysfunction 
in diabetic patients could show a relevant importance of this drug in both 
type 1 and type 2 diabetes in preserving the endothelial impairment; 
however even if this hypothesis is sustained by powerful studies in the 
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The endothelium, considered for long time as passive barrier between the 
blood stream and the surrounding tissues, is now recognized to play an 
active role in regulating blood fluidity and pressure, and refraining plasma 
proteins and leukocytes from extravasation. Blood pressure regulation is a 
highly dynamic process that is determined by the integration of chemical 
and rheological stimuli on the vascular wall [109]. Among all the factors 
released by the endothelium, nitric oxide (NO) is of critical importance to 
maintain blood pressure homeostasis [110, 111], and alteration of NO 
bioavailability strongly contributes to increase in vascular resistance [112]. 
Bradykinin, acetylcholine, vascular endothelial growth factor (VEGF), as 
well as blood flow, strongly induce eNOS activation and NO-mediated 
vascular tone regulation. 
In addition to NO, the endothelium releases other vasorelaxing factors, 
such as prostacyclins and endothelial-derived-hyperpolarizing factor 
(EDHF). Endothelium derived contracturant agents (EDCF), endothelin 
and prostanoid play an important role particularly when the endothelium is 
activated, such as during inflammation. The increase of Ca2+ influx in 
endothelial cells leads to activation of eNOS and increase of NO 
production, stimulation of phospholipase A2 (PLA2) enzyme involved in 
the production of arachidonic acid as precursor of PGI2 and opening of 
potassium channel currents representing the classical EDHF response. In 
vascular smooth muscle cells (VSMC) EDCF stimulates G-protein coupled 
receptors (GPCRs) leading to increase in calcium, phosphorlitation of 
myosin light chain (MLCP) and vessels contraction. 
The lack of the endothelium to accomplish any of these tasks is defined 
endothelial dysfunction [112, 113], which is an early event in the 
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pathogenesis of multiple cardiovascular diseases including hypertension. 
In this condition, endothelial-derived contractile factors prevail over the 
vasorelaxant mediators, resulting in enhanced peripheral resistances and 
increase in BP [48, 114].  
Emerging line of evidence suggest an important role of sphingolipids, a 
class of lipids, in the regulation of cardiovascular functions, in 
physiological and pathological conditions. 
 
1.1 Sphingolipids: biosynthesis, sources and transport 
Sphingolipids (SL) are important components of plasma membranes and 
contribute to maintain the integrity of the cells. However, in the past three 
decades they have come to the foreground as bioactive lipids regulating 
different cellular processes including apoptosis, growth, differentiation, 
migration, inflammation, invasion, metabolism and angiogenesis [115, 
116]. Sphingosine (Sph), ceramide (Cer) and sphingosine-1-phosphate 
(S1P) are the best characterized. Sphingosine has a role in regulating 
the actin cytoskeleton, endocytosis and apoptosis, ceramide is mostly 
involved in the cell responses to the stress, while S1P has a crucial role 
in cell survival, cell migration and inflammation [117]. However, other 
molecules belonging to this family, such as ceramide-1-phosphate, 
glycosphingolipids (GSL) and sphingomyelins (SM), also play relevant 
roles in inflammation and intracellular trafficking.  
Sphingolipids are composed of a polar head group attached to a non-
polar tail, and their core is represented by the long-chain amino alcohol, 
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sphingosine (Figure 1.1). Modification of this basic structure is what gives 
rise to the vast family of sphingolipids. 
         
          
Figure 1.1. Sphingosine and related sphingolipids. Different chemical reactions allow 
the continuous inter-conversion of sphingolipids, as sphingomyelin, ceramide, ceramide-1-phosphate 
and sphingosine-1-phospahate which always maintain the structural core of sphingosine. 
 
Sphingolipids are generated through three different pathways: the de 
novo biosynthesis, a direct hydrolytic pathway and the salvage pathway 
[117]. The de novo biosynthesis begins in the cytosolic leaflet of the 
smooth endoplasmic reticulum (ER), with the condensation of palmitoyl-
CoA and serine, catalyzed by the pyridoxal phosphate-dependent 
enzyme, Serine Palmitoyltransferase (SPT) to generate the 3-keto-
dihydrosphingosine. Since this represents the first reaction of the de 
novo sphingolipids biosynthesis, SPT controls the first rate-limiting step 






The highly conserved SPT enzyme belongs to the oxamine synthases 
family and acts as a membrane-bound heterodimer composed of two 
subunits, first identified in the yeast as Lcb1/Lcb2 [118-120]. However, 
these are replaced by the corresponding homologous subunits in 
mammalian cells; the serine palmitoyltrasnsferase long-chain subunit 1 
(Sptlc1) is the only homolog for the Lcb1, whereas Lcb2 can be 
substitute by the Sptlc2 or Sptlc3 [121, 122]. It has been confirmed that 
the active catalytic site of the SPT is expressed at the interface between 
the two subunits, thus, they are both necessary to preserve the SPT 
activity. Indeed, it has been shown that mice knockout for Sptlc1 or 
Sptlc2 are embryonically lethal, suggesting the importance of the two 
subunits during the development; however, while Sptlc1 is present in all 
catalytically active SPT enzymes, the presence of Sptlc2 or Sptlc3 
depends both on the tissues where SPT enzyme is expressed and on the 
cellular sphingolipids requirement. 
Following the formation of the 3-ketosphinganine, a NADPH dependent 
reductase converts this compound to dihydrosphingosine, also called 
sphinganine, and this molecule is then N-acylated to produce 
dihydroceramide. Subsequently, oxidation of the dihydroceramide by 
dihydroceramide desaturase generates ceramide. Central metabolite of 
this metabolic pathway, ceramide, not only shows its biological role in cell 
processes, but it represents also the start point for the synthesis of the 
other bioactive sphingolipids. Modification on the C-1 of the Cer can 
generate ceramide-1-phosphate (C1P) through phosphorylation, which 
then is metabolized in glycosphingolipids (GSL) and sphingomyelins 
(SM), high order sphingolipids. These kinds of metabolization processes 
do not take place in the ER anymore. Cer can be transported to the Golgi 
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through the action of a ceramide transfer protein CERT which couples 
the molecule to the SM synthesis by transferring phosphorylcholine from 
phosphatidylcholine to ceramide in a reaction catalyzed by 
sphingomyelin synthases (SMS) [123], moreover ceramide can be 
transformed in GluCer, and then transported by the protein FAPP2 in 
Golgi apparatus where it is metabolized in GSL. At this point, SM and 
GSL are transported to the plasma membranes of the cells by a vesicular 
trafficking.  
Plasma membrane SM can become sources for ceramide production by 
sphingomyelinase, which is then hydrolyzed in sphingosine (Sph) by a 
ceramidase. This represents the second important pathway involved in 
the intracellular sphingolipids production and ending with the 
phosphorylation of Sph by sphingosine kinases (Sphk1 and Sphk2) in 
order to obtain sphingosine-1-phosphate (S1P), a high bioactive lipid.  
Moreover, recycling pathways of SL mainly interconnects with the de 
novo biosynthetic pathway to maintain cellular SL homeostasis at low 
energy cost. SL from plasma membrane, as well as from extracellular 
fluids, can be internalized in lysosome and degraded in ceramide, which 
can be further metabolized as aforementioned. The integration of these 
two pathways preserves intracellular sphingolipids levels in a 
physiological range, essential to preserve both the structure and the 




Figure 1.2 Sphingolipids metabolism and compartmentalization. In the ER, Serine Palmitoyl CoA 
starts the de novo sphingolipid biosynthesis by mediated the condensation between Serine and 
Palmitoyl CoA (1) in order to generate 3-Keto Sphinganine and other sphingolipid, which are 
subsequently converted until the formation of ceramide (2). Ceramide from the ER membrane is then 
transported to the Golgi apparatus where is metabolized in high order sphingolipids, as 
Sphingomyelins (3) and Glycosphingolipids (4). By a vesicular transport SM and GSL move to the cell 
plasma membrane (5). Here, GSL mainly act as membrane components (6), whereas most of the SM 
is metabolized to form again ceramide (7). In plasma membrane a ceramidase converts ceramide in 
Sphingosine (8), which is then phosphorylated b a sphingosine kinases in Sphingosine-1-Phosphate 
(9). Endocytic vesicles recycle SM and GSL from plasma membranes and from extracellular fluid in 
order to be degraded in ceramide, which is then converted again in new sphingolipid molecules (GSL, 
SM and Sphingosine) (10). Sphingosine and S1P are also recycled from the plasma membrane and 
can be metabolized in ceramide in ER membrane (11).  
These are called “sphingolipid salvage pathways”. 
 
Sphingolipids are distinguished by their specifically biophysical 
proprieties on which depends their subcellular localization. Indeed, in 














the site of generation of sphingolipids represents also the site of their 
action. This represents the reason why most of the enzymes of 
sphingolipids metabolism are localized where these molecules show their 
regulatory functions. SL can be separated depending on their biophysical 
proprieties, for examples: C1P carries ionic charges at neutral pH and 
also contains two hydrophobic chains, thus for this composition C1P 
mostly reside in its compartment of generation without flipping across the 
bilayer; ceramide, instead, for its hydrophobic composition can flip across 
the membrane; whereas sphingosine, S1P and also sphingomyelin are 
characterized by sufficient aqueous solubility that allows them to move 
between the membrane and the cytosol without transporters [117]. 
However, cells contain particular protein transporters that can deliver 
sphingolipids across the membrane or between different membranes 
inside the cytosol. We have previously talked about the protein CERT 
which delivered ceramide for SM production in the Golgi apparatus and 
the protein FAPP2 involved in the synthesis of glycosphingolipids, 
however there are also present in the plasma membrane other two 
transporter belonging to the ABC transporter superfamily [124]. These 
are particularly involved in the S1P influx and efflux through the 
membranes. S1P is produced in the inner leaflet of the plasma 
membrane, but it is well know that its biological function depends on its 
interaction with the S1PRs expressed on the outer leaflet. The cystic 
fibrosis transmembrane regulator (CFTR) and the ABCC1 transporters 
have been identified as the two mainly structure involved in S1P 
internalization from the extracellular environment, and S1P efflux 
respectively [125, 126]. Moreover, recently by Fukuhara and colleagues 
has been discovered another S1P transporter specifically in endothelial 
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cells, named spinster-2-transporter (Spns-2). They shown that once 
produced in EC, S1P is transported outside where activate its receptors 
inducing protective functions and regulating vascular tone [127].  
Several studies sustain that a great amount of SLs derive from the 
circulating system, where many of the enzymes as ceramidase, 
sphingomyelinase and sphingosinkinase have been detected mostly in 
association with circulating lipoprotein enriched of sphingomyelin and 
ceramide [117]. Moreover, erythrocytes, endothelial cells [128, 129] and 
platelets [130] represent the major sources of S1P in the plasma where it 
is bound to apolipoprotein M (ApoM) of HDL (≈60%) and albumin (≈30%) 
reaching a concentration between 0.1uM and 1uM [131]. Plasma 
circulating sphingolipids can be internalized by the surrounded cells and 
used for recycle [132]. Exogenous sphingolipids can enter into cells as 
free molecules, or as lipoprotein complexes. While monomers of 
sphingolipids can cross the cell plasma membrane, lipoproteins are 
internalized by endocytosis. In both cases, internalized sphingolipids are 
catabolized in sphingosine and then recycle for the production of new 
bioactive molecules [132]. 
Thus, sphingolipids production and transport inside the cells is precisely 
organized, and preserves the role of these molecules as essential 
membrane components as well as their biological function 
 
1.2 Shingolipids: plasma membrane composition 
Plasma membrane not only confers a spatial identity to the cells but also 
represents a barrier between intracellular and extracellular environment. 
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In the same way, intracellular organelles are also delineated by plasma 
membrane allowing the separation from the surrounded cytosol. These 
membranes are generated by interaction between lipids and proteins. 
Lipids are amphipathic molecules containing a non-polar hydrophobic 
domain and a polar hydrophilic portion, which rapidly interacts with the 
water. During the formation of the bilayer, the hydrophobic portions 
spontaneously interact each other, while the hydrophilic moieties tend to 
self-associate and interact with the intra or extracellular environment, thus 
generating two parallel leaflets, one in contact with the cytosol (baso-
lateral membrane), and the other with the extracellular fluids (apical 
membrane). The major lipid components of the eukaryotic plasma 
membrane include glycerolphospholipids, as phosphatidylcholine (PC), 
phosphatidylserine (PS) and phosphetanoammina (PE), sphingolipids, like 
SM and GSL, and cholesterol. Lipids are distributed in the plasma 
membrane in order to obtain an asymmetric organization between the two 
leaflets. While PC, PS and PE are mostly distribute in the outer leaflet (the 
extra cytosolic portion), SM and GLS are predominantly present in the 
inner leaflet (cytosolic portion) [124]. Lipids can translocate from a leaflet 
to another by “flip-flop” indicating with “flip” the movement from the extra 
cytosolic to the cytosolic portion, while “flop” is the opposite direction. 
However, the polar head of SM and GSL makes difficult this kind of 
translocations through the hydrophobic interior of the membrane 
therefore, plasma membrane has three different protein which act as lipid 
translocases [124]: 1) a sub-family of P-type ATPase, known as amino 
phospholipids translocases which mediate the flip of PS and PE 
specifically; 2) ATO-binding cassette, also called ABC transporter which 
move to the outer leaflet GSL and SM; and the 3) lipid scramblases which 
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move all glycerophospholipids classes through the trans bilayer [124]. 
These transporters and the movements of lipids within the bilayer make 
the membrane a fluid mosaic where hosted functional proteins can 
differently distribute.  
The characteristic asymmetry and fluidity of the plasma membrane are 
important to preserving the physiological functions of cells. For instance, 
the loss of SM in the outer leaflet and the trapping of PE on extracellular 
surface alter the formation of the cleavage furrow during cytokinesis 
leading to a stopping of the cellular division. Moreover, expression of PS 
on the cell surface is associated to disruption of cell asymmetry and 
consequent apoptosis due to inhibition of myotubule formation and 
consequent cell division arrest [133]. Moreover, PS on the cell membrane 
surface represents also a trigger for blood coagulation, thus showing a 
significant pro-coagulant effect [134]. In this context, Annexin V, which 
have high affinity for PS, could be used as a direct index for plasma 
membrane alteration.  
Membrane is considered not only a barrier for the cells and for the other 
intracellular organelles, but it is also the site where many cellular 
machineries carry out their function [135]. For several decades, the 
research on plasma membrane was dominated by the hypothesis that 
proteins were the key factors for the function of the membrane while lipids 
represented only a fluid solvent [124]. However, from the 1997 to date the 
idea is changed, and plasma membrane is considered a biological 
structure governed by sphingolipids-cholesterol-proteins interactions, 
which are essential to maintain the cellular bioactivity.  
106	  
	  
The dynamic clustering between SL and cholesterol within plasma 
membrane form particular compartmentalization, or subdomains, called 
lipid raft [136]. In these microdomains, the dynamic assemblies of 
cholesterol and sphingolipids, in particular glycosphingolipids and 
sphingomyelins, are mainly concentrated in the exoplasmic leaflet of the 
bilayer: here, hydrophobic and hydrophilic bounds allow the interaction 
between the satured hydrocarbon chains as well as the polar heads of the 
sphingolipids whereas the cholesterol, as a molecular spacer, fills all the 
voids between the molecules [137]. On the other side, the inner leaflet of 
rafts is enriched not only of cholesterol but also of phospholipids, which 
are the mainly components of non-raft regions [138, 139]. However, 
whereas non-raft regions are characterized by unsatured phospholipids, 
rafts microdomains are highly enriched in saturated fatty acids, allowing 
for the close packing of lipids within rafts, compared with the surrounded 
non rafts membrane regions [138, 139]. Indeed, as a result of the 
presence of cholesterol and saturated fatty acids, lipid rafts are more 
ordered and less fluid than the surrounding membrane [140].  
The existence of the two different lipid organizations between the two-
membrane leaflets implies that rafts could be considered as bilayer 
structure as well as the whole membrane. They appear to be small in size, 
with a diameter between 100-200nm, but may constitute a relatively large 
fraction of plasma membrane [136]. 
Biosynthesis of these microdomains starts in the ER where cholesterol 
and ceramide are produced and concentrated in vesicles direct to the 
Golgi apparatus. Here, vesicles became more enriched of ceramide-
derived sphingolipids, as SM and GSL, as well as cholesterol and other 
synthesized lipids such as PC, PE and PS [141]. 
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Glycosylphosphatidylinositol (GPI)-anchor proteins (GPI-AC) bind these 
vesicles and mediated their transport from the ER-to-Golgi, and finally the 
segregation from Golgi-to-plasma membrane [142]. Defects in GPI-anchor 
synthesis dramatically reduced the total membrane sphingolipid levels 
leading to a disruption of the membrane rafts compartmentalization. 
Moreover, cytoplasmic proteins that are covalently modified by saturated 
fatty acids (palmitoyl or myristoyl moieties) and transmembrane proteins 
could be attached by GPI-anchor protein and thus can be segregated 
within the lipid rafts in the cell surface [143].  
The tightly packed and the highly order construction as well as the 
relatively higher lipid/proteins, give rise to define lipid rafts as detergent-
resistant low-density microdomains (DRM) [135, 136]. For this reason, 
lipid rafts have been physically isolated based on their combination of low 
density and insolubility in detergent. Typically, cells are scraped into cold 
buffer containing 1% Triton X-100 and then the lysate is homogenized 
[144]. Rafts are then isolated by flotation in a 5% to 30% sucrose density 
gradient where they distribute in the top few fractions of the gradient (low 
density portions) [144]. This procedure yields to a consistent product that 
is enriched in cholesterol and then using raft marker proteins, such as 
GPI-anchor proteins or flotillins, raft microdomains can be separated from 
the surrounded membrane [136]. 
It has been recognized the existence of two kind of “low density, 
detergent-resistant membrane”, distinguished in non-caveolar lipid rafts 
and caveolar lipid rafts, where formation of caveolae takes place [145]. 
Caveolae are small plasma-membrane invaginations that can be viewed 
as a subset of lipid rafts. They are also enriched of cholesterol and 
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sphingolipids, however they are distinguished from the lipid rafts by the 
presence of caveolin proteins [146] (Caveolin-1, -2, -3) which bind the 
cholesterol and appear to be mainly responsible for stabilizing the 
invaginated structure of the caveolae [147, 148].  
As lipid rafts, caveolae also exhibit a resistance to detergent extraction 
and thus they can co-isolated with the non-caveolar fraction by low-
density flotation centrifugation [149-152]. However, it is necessary to 
separate them in order to perform specific biochemical analysis in their 
lipid and protein composition. In this regard, Yao Y. and colleagues in 
2009 used a modified four-step sucrose density gradient to separate 
caveolae from other non-caveolar lipid microdomains which are 
recognized by protein marker specifically expressed in one of the two 
compartments, as Gangliosides (GM), Caveolin-1 (Cav-1), Flotillin-1 (Flot-
1) and Thy-1 (Thy) which represents a GPI-anchored protein (Figure 1.3). 
      
Figure 1.3 Yao Y. et al. Cell Research, 2009. Separation of caveolae and non-caveolar lipid 
microdomains from purified plasma membrane of 3T3-L1 cells. (A) Modified four steps sucrose 
density gradient. (B) Analysis of lipid-microdomains associated proteins: Gangliosides (GM) is the major 
lipids in characterizing the non-caveolar lipid microdomains [153], Cav-1 is marker protein for caveolae, 
Flotillin-1 (Flot-1) represents a integral component of caveolae and also have been suggested to 
interact with caveolins, then Thy-1 (Thy) which represents a GPI-anchored protein. 
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It is well known that both caveolae and lipid rafts lipid rafts are composed 
by cholesterol, sphingolipids, and phospholipids [136], however Yao Y and 
colleagues demonstrated that the amount of cholesterol and 
sphingomyelin, as well as PE and PC are higher in non-caveolar lipid rafts 
compare to caveolae subdomains, pointing out possible differences in 
fluidity and lipid-order between the two plasma membrane microdomains, 
which could be correlated to a different partitioning as well as function of 
cytosolic and membrane  proteins. However, other studies reported that 
cholesterol is more enriched in caveolae because the ability of caveolin 
proteins to binding it [146].  
Beside these differences in the composition, a variety of proteins have 
been found to be enriched in lipids rafts and/or caveolae. These include 
caveolins, flotillins, GPI-anchor proteins, heterodimeric G-proteins, SRC 
family kinases, growth factors receptors, as well as MAP kinase, protein 
kinase C and also eNOS enzyme [144, 154-157]. The mechanisms 
through which raft associations occur seem to be variable, however the 
ordered-lipid organization mediates and regulates the portioning of the 
associated proteins and receptors during their activity or basal conditions. 
 
1.3 Lipid raft and it role in endothelial neurotransmitter 
signaling 
Lipid rafts have been implicated in a variety of cellular processes including 
protein and lipid trafficking [158], viral infection [159] and signal 
transduction [137]. Many proteins involved in cell signaling, including 
receptors, low molecular weight G protein and heterodimeric G protein, 
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have been shown to be enriched in lipid raft [136, 154]. Depletion of 
cholesterol from plasma membrane microdomains has been associated to 
alteration of the signal transduction from the physiological condition, 
suggesting that cholesterol-rich domains participate in the control of cell 
signaling [136]. 
In the simplest case, rafts can represent a signaling platform that spatially 
localizes all pathways’ components facilitating their interactions and 
promoting the signaling. Receptors, coupling factors, effector enzymes 
and substrates of a specific signaling pathway are localized in the lipid 
rafts. This spatial proximity favors a rapid and efficient activation of the 
signaling transduction pathway following the binding of the receptor by the 
ligand. [136]. Moreover, receptors can be localized in a particular class of 
rafts containing all the components necessary for the transduction in order 
to increase the specificity of signaling [136]. On the contrary, 
complementary components of a signaling pathway, such as membrane 
bound enzymes and receptors, are segregated in different lipid rafts, 
which merge following the ligand-mediated activation of the receptors 
[136]. Lastly, receptors or signaling transduction molecules can localize in 
non-raft regions, and only upon their activation, localize to the rafts 
domains together with signaling transduction molecules leading to the 
activation of the intracellular pathway. In conclusion, rafts can regulate the 
receptor-activated signaling pathway by compartmentalizing the receptors 
and their interacting partners in separated membrane rafts [149], 
preventing an hyperactivation of these pathways [136]. Therefore, the 




Moreover, in the lipid rafts have been reported regulatory molecules able 
to modulate the receptor activation. For instance, in endothelial lipid rafts, 
caveolin-1 (Cav-1) is one of the major regulatory molecules. Cav-1 is a 
member of a family of homologous molecules localized to cholesterol-
enriched low-density membrane domains. Cav-1 is present in the striated 
coat that is seen surrounding caveolae in the electron microscope [149]. 
With the exception of the endothelial insulin receptor (IR), Cav-1 binds to 
and inhibits growth factors tyrosine-kinase receptors, as well as S1PR1, a 
Gi-protein coupled receptor, and also eNOS enzyme. Indeed, Cav-1 
knock-out mice show insulin resistance and decreased insulin receptor 
expression in adipose tissue, defects in nitric oxide and calcium signaling, 
as well as an enhancement of basal and S1P and VEGF-induced 
activation of Akt [160]. In addition, the distribution of tyrosine-kinase 
receptors, eNOS and G-protein coupled receptors is not affected by 
knocking out of Cav-1, suggesting that this regulatory molecule is not 
necessary for the localization of signaling proteins to lipid rafts, but for the 
modulation of their function [161]. 
Many raft proteins localized to lipid rafts, also partition to non-raft portions 
of the membrane, where they interact and activate different subsets of 
signaling partners. Changes in lipid composition of the rafts, such as the 
depletion of cholesterol, affect the partitioning of signaling molecules 
between raft and non-raft compartments, altering the activation signaling 
pathway.  
Rafts may also play a role in signal termination. Rafts are known to be 
involved in endocytic events [147, 150], and could limit cell signaling by 
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internalizing specific components, preventing them from further 
participation in a particular pathway. 
Considering the importance of preserving lipid raft composition to maintain 
proper intracellular signaling mechanisms.  
1.3.1 Lipid raft and regulation of G-protein coupled receptors 
signaling 
G-protein coupled receptors are the most abundant class of receptors in 
the human body. These receptors are transmembrane proteins showing 
the ligand-binding site on the extracellular surface whereas possess on 
the intracellular region a unique class of signaling molecules called G 
protein which regulate the intracellular messengers (G proteins are so 
named since they bind the guanine nucleotides GTP and GDP). Each 
transmembrane region consists of a single α helix, and the α helices are 
arranged in a characteristic structural motif that is similar in all membranes 
of this receptor class. In the resting state (non-stimulated), the cytoplasmic 
domain of the receptor is non-covalently linked to a G protein complex 
formed of α and βγ subunits. Upon activation, the α subunit exchanges 
GDP for GTP. The α-GTP subunit then dissociates from βγ subunit, and 
they both cross the inner leaflet of the plasma membrane to interact with a 
number of different effectors. These effectors include adenylate cyclase, 
phospholipase C, various ion channels, and other classes of proteins. 
Signal mediated by G proteins are usually terminated by the hydrolysis of 
GTP to GDP, which is catalyzed by the inherent GTPase activity of the α 
subunit.  
The intracellular molecular pathways recruited by the GPCRs are strictly 
dependent on the typology of the α subunit, indeed a large number of Gα 
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protein isoforms have been identified, with specific effect on their target. 
The most common are distinguished in Gαs, Gαi , Gαq and   Gα12/13): 
-­‐ Gαs induces the activation of adenilate cyclase; 
-­‐ Gαi or Gαo have an inhibitory effect on the adenilate cyclase activity; 
-­‐ Gαq is responsible of the a Ca2+ intracellular levels increase; 
-­‐ Gα12/13 is involved in the cytoskeleton proteins regulation by a Rho-
GTPase. 
Moreover, the βγ complex of the G proteins can also act as second 
messenger molecules, although their actions are not as thoroughly 
characterized. 
Synthesis of GPCRs starts in the ER where they form either homo- or 
heterodimeric structures. Following ER exit, GPCRs transit through the 
Golgi apparatus and they undergo through additional modifications, such 
as oligosaccharide processing, fatty acylation and/or myristoylation in 
order to allow their final segregation in the lipid rafts. Indeed, at the end of 
these chemical reactions, GPCRs are packaged in exocytic transport 
vesicles and enter the endosomal system where they are subsequently 
targeted to the plasma membrane [162]. 
A large number of G-protein-coupled receptors are enriched in the lipid 
rafts or caveolae. This includes β1- and β2-adrenergic receptors, 
adenosine 1 (A1) receptor, angiotensin II type 1 (AT1) receptor, bradykinin 
B1 and B2 receptors, S1P1 receptor (S1PR1) and also muscarinic 
cholinergic receptor M2 [163-171]. Switching from inactive and active 
state, these receptors differently move between raft and non-raft region 
and mediate their intracellular signaling. Indeed, A1 and β2-adrenergic 
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receptor initially localize in the lipid raft and subsequently translocate into 
non-raft membranes after activation, whereas M2, AT1, S1PR1 as well as 
B1 receptors are targeted to the rafts upon activation by the agonist. Thus, 
ligand interaction induces changes in the receptor localization between 
raft and non-raft compartments. Moreover, ligands can also induce the 
translocation of the receptors into the lipid rafts, where G proteins and 
effector enzymes are localized to promote the development of the 
signaling. However, for some GPCRs, such as muscarinic acetylcholine 
receptor or AT1, interaction with the substrate leads to desensitization via 
a mechanism which involves the sequestration of the receptor from the 
cell surface [172] since both caveolar and non-caveolar lipid rafts  are 
known to be involved in the endocytosis [137, 147, 150, 154]. Thus, for 
receptors that are recruited into the lipid rafts following agonist activation, 
it is possible that recruitment of rafts not only initiates signaling but also 
represents the first stage of the desensitization of the signal. 
Caveolins have been shown to interact with several GPCRs regulating 
their signaling, as A1 receptor, M2 receptor, and also B2 receptor. The 
interaction with caveolin not only serve for the localization of the receptor, 
but also profoundly influence signaling from certain neurotransmitter 
receptors, indeed Cav-1 is known to be a lipid raft regulatory protein [173]. 
A particular experiment has used the “caveolin scaffolding domain“ as a 
bait to screen a library of synthetic peptides containing a motif able to bind 
Cav-1. GPCRs as α-adrenergic receptor, muscarinic receptor, endothelin 
receptor have been found to contain this peptidic motif but it is still 




After their segregation in the lipid rafts, localization of G-protein coupled 
receptor depend on their distribution between planar lipid raft and 
caveolae microdomains. However, a paper of Phil Oh in 2001 showed that 
after isolation of caveolae from other non-caveolar lipid raft microdomains 
in endothelial cells, it has been observed that Gαq-protein interacts directly 
with caveolin, targeting the receptor in the caveolae, while Gαs, Gαi are 
targeted to lipid raft that does not contain caveolins [175] [176] (Figure 
1.4). It has been reported that AT1 receptor, as a Gαq protein-coupled 
receptor, even if contains the “caveolin scaffolding domain”, it is highly 
expressed in non-caveolar lipid raft. However, mutations of the “caveolin 
scaffolding domain” causes a reduction of AT1 expression on cell surface, 
meaning that Cav-1 bound has an important role in mediating the receptor 
sorting in plasma membrane even if it will be not localize in caveolae 
domain [177]. 
               
Figure.1.4  Phil O. et al. Molecular Biology of the Cell. 2001. Receptors localization in caveolae (V) and 
lipid rafts (LR), isolated from endothelial cell plasma membrane. Gi and Gs appear to be concentrated 
primarily in the lipid raft, while Gq is preferentially associated to caveolae  
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Thus, different G proteins may segregate into different subtype of lipid 
rafts depending on the presence of other components of the cells. Beside 
their localization it has been reported that an intact lipid rafts is necessary 
for the G protein-mediated signaling, indeed alteration of the lipid 
composition could affect the shift of the receptor from basal to active state 
and vice-versa. This has been confirmed by in-vitro experiments in cells 
treated with methyl-β-cyclodextrin, which is known to cause extraction of 
cholesterol from plasma membrane. Depletion of cholesterol destroys the 
tight lipid-order of the lipid rafts. This negatively affects the signaling of G 
protein targeted in the lipid rafts upon their activation, whereas facilitating 
the pathways mediated by G protein, which translocate in non-raft 
domains after activation. Indeed, depletion of cholesterol has been 
associated to impairment of particular G-protein mediated signaling, such 
as bradykinin-stimulated phosphatydil-inositol turnover [178], as well as 
thrombin–stimulated phosphatidic acid generation and phosphatidyl-
inositol 3,4,5 triphosphate production is inhibited by cholesterol depletion 
[179]. On the contrary, both myocyte contraction and adenilate cyclase 
activation mediated by β2-adrenergic and adenosine-1 receptors, 
respectively, are enhanced by cholesterol depletion [165, 166], whereas 
supplementation of cholesterol and their fixation in the lipid raft 
environment inhibit the activity.  
These findings suggest the important role that cholesterol and lipid rafts 
composition play in the regulation of G protein signaling, which is also 
dependent not only on the localization of the receptors in the lipid rafts or 
caveolae, but also on the partitioning of these protein between the rafts 




1.3.2 Lipid raft and regulation of Tyrosine kinase signaling 
Tyrosine kinases receptors are another prominent example of proteins 
involved in cell signaling that are enriched in lipid rafts. Epithelial Growth 
Factor receptor (EGF), Vascular Endothelial Growth Factor (VEGF), 
Insulin receptor (IR), Nerve Growth Factor receptor (NGF), Platlet Derived 
Growth Factor receptor (PDGF) and others have been localized to low-
density cholesterol-enriched membrane domains and their function is 
strictly regulated by cholesterol content [158]. TK-associated receptors 
constitute a diverse family of proteins that, although lacking inherent 
catalytic activity, recruit active cytosolic signaling proteins in a ligand-
dependent manner. They are present in the membrane as monomer and 
only upon binding of their ligand,they cluster together to generate a dimer, 
leading to activation of the intracellular tyrosine kinases activity of the 
receptor [180]. At this point, the receptor auto-phosphorylate in trans in 
the C-terminus generating phosphor-tyrosine residues that serve as 
binding sites to recruit cytoplasm proteins that are then activate to 
phosphorylate other proteins on tyrosine residues involved in the process 
of the signaling transduction [181, 182]. EGF, PDGF, VEGF and others 
TK receptors follow this activation mechanism since they are segregated 
as monomer on plasma membrane, on the contrary, IR already appears 
as dimer. Two different subunits, alpha and beta interacts each other 
through disulfide-bound forming a monomer where the alpha contains the 
binding site for the insulin, while beta subunit has the tyrosine kinases 
domain. IR is a dimer formed by two disulfide-bound alpha-beta units. 
Interaction of the ligand on the extracellular portion [182] of the alpha 
subunits modifies the conformation of the receptor within the hetero-
tetrameric structure leading to the activation of the tyrosine kinase activity 
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[183, 184]. Moreover, IR, is also associated to Insulin Receptor Substrate 
(IRS) which are phosphorylated on tyrosine residues by the respective 
receptor upon its activation, and serve as adapter proteins for the 
formation of the protein-protein complexes necessary for signal 
transduction [185-187]. 
As the GPCR, also the TK receptor could differentially segregate in 
caveolar and non-caveolar lipid rafts. When the physical separation of 
these two lipid rafts subdomains became possible, different studies have 
been carried out to specifically determine into which of these two classes 
of low-density membrane domains the receptor actually partitioned. These 
kind of experiments have been performed mostly using the electron 
microscopy analysis where TK receptors were labeled with gold in order to 
determine if the target receptor is present within the caveolar 
invaginations or whether their presence in localize on the flat lipid rafts. 
These experiments pointing out the evidence that the distribution of  EGF 
is distinct from that of caveolae and immunoprecipitation analysis also 
showed that in non-stimulated conditions the EGF receptor is separated 
from the caveolin-containing membrane domains. However, stimulation of 
the EGF leads to the loss of this receptor from the lipid rafts domain 
toward a localization in non-raft membranes. Contrarily, IR largely 
localizes in caveolae, indeed immunogold electron microscopy 
demonstrated that insulin receptors are essentially restricted in caveolae 
domain in both 3T3-L1 [188] and human-derived adipocytes [189]. 
Likewise the IR, PDGF and VEGF receptors are also associated with 
caveolar lipid rafts and upon ligand-binding receptors partitioning in the 
lipid raft rather then non-raft region. However, it has been reported that in 
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cells lacking of caveolae, IR is localized in non-raft plasma membrane but 
insulin stimulation enhances the affinity for raft domains. 
The observation that membrane receptors move in or out of lipid rafts 
following hormone stimulation suggest that their association with specific 
membrane microdomains is not permanent but is subjected to regulation. 
The association of tyrosine kinases receptors with rafts or caveolae is an 
equilibrium process that can be shift in one direction or another based on 
external condition. Indeed, depletion of cholesterol drastically affects TK 
function as happened for GPCR.  Treatment with methy-β-cyclodextrin 
leads to the flattening of the caveolae, which disappear from the cell 
surface. Despite this event receptors do not change their membrane 
distribution, indeed insulin receptor remains associated with the residual 
part of caveolae but depletion of cholesterol reduces its activity since upon 
insulin stimulation, phosphorylation of IRS as well as stimulation of 
glucose uptake inside the cells are decreased [188, 190-192]. Likewise, 
PDGF-, VEGF-mediated signaling diminishes upon cholesterol depletion, 
whereas EGF-mediated signaling is up-regulated. Indeed, disruption of 
lipid rafts was shown to enhance EGF-induced receptor dimer formation 
and auto-phosphorylation, whereas cholesterol loading is associated to an 
inhibition of receptor activation [193]. EGF in the only receptor that moves 
into the non-raft membranes after stimulation, thus disruption of the lipid 
rafts facilitates its movements outside the microdomains enhancing its 
activity. 
Based on all the findings relating to GPCR and TK receptors, we can 
affirm that lipid rafts composition affects the localization and the function 
of the binding receptors, altering the membrane fluidity, thickness and 
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clustering of the same receptors and other effector proteins both in 
caveolar and non-caveolar domains. In this scenario, as cholesterol 
causes a disruption of the lipid rafts after depletion, it is intuitive that SL 
levels needs to be tightly regulated in order to preserve the biological 
function of cells. Recently, the alteration sphingolipid levels has been 
associated to several disorders such as myocardial infarction, 
hypertension, stroke, diabetes mellitus type 2 and obesity. However, the 
specific molecular mechanism controlling SL metabolism and the impact 
of these changes on the pathogenesis of these diseases are poorly 
understood. 
 
1.4 Sphingolipids and cardiovascular homeostasis 
Sphingolipids biologically participate in several cellular functions. The 
three-sphingomyelin metabolites, ceramide, sphingosine and the 
sphingosine-1-phospate (S1P) are the main protagonists, of the 
sphingolipids class, playing an active role in regulation of the homeostasis 
of several different cell type. Indeed, sphingolipids give their contribution 
in the development and the regulation of mitogenesis, cell growth, 
inflammatory response, and cardiovascular homeostasis acting on 
different regulatory molecular pathway. In pathological state, where these 
pathways is altered, regulation of sphingolipids synthesis and production 
can represent a possible good approach to restore the physiological 
conditions of the organism. 
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The role of sphingolipids in the cardiovascular system it has been well 
studied, however there are several controversial hypothesis that still have 
to be clarified. 
In the field of the cardiac physiology, it has been show that overproduction 
of SL, such as sphingomyelin and ceramide, causes a severe damage to 
the cardiac function through both acute and chronic effects [194]. Indeed, 
increased SL levels in myocardial cells enhances the chronotropic and 
inotropic action of the heart, following apoptosis and hypertrophy process 
during the time [195]. Pathological state, such as the ischemic/reperfused 
heart, shows a decrease of the cardiac contractility and myocardial 
apoptosis probably due to an increase of TNFα production and inhibition 
of ceramidase and sphingomyelinase which then leads to an increase of 
sphingolipids levels and worsening of the cardiac function [196]. 
Moreover, oxidative stress in myocardial cells is associated to depletion of 
glutathione, which is involved in the regulation of sphingomyelinase and 
ceramidase. Activity of these enzymes is down regulated in absence of 
glutathione with consequent drastically increase of sphingolipids levels to 
a pathological range [197]. Indeed, glutathione precursor, N-acethyl-
cysteine is able to restore ceramide and sphingosine recycle and re-
stabilize cardiac function [198]. On the other hand, it has been also 
discovered that S1P, as other sphingolipids, protects the heart from 
inflammation, fibrosis and loss of function during a cardiac pressure 
overload through S1P/S1P1r/eNOS signaling activation [199]. These 
evaluations are also in line with the evidence that S1P plays also an 
important role in vascular homeostasis through the activation of eNOS/NO 
endothelial pathway. Thus, cardiomyocytes-derived sphingolipids are the 
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necessary to sustain the heart function, however they need to be 
contained in a physiological window in order to preserve cardiac damage.  
Our attention has been more focused on the role of sphingolipids in 
vascular homeostasis regulation. Ceramide and S1P are the most lipids 
which show an active role in the new vessels formation (angiogenesis), 
endothelial barrier integrity maintenance and most important in the 
regulation of the vascular tone. There are different studies that have 
shown controversial hypothesis about the role of ceramide in the 
vascular tone regulation. Igarashi et al in 1999 have demonstrated a 
vasorelaxant effect of ceramide in isolated vessels as activator of 
eNOS/NO pathway [200], whereas other hypotheses sustain a role of 
ceramide in vascular homeostasis by inhibiting eNOS activity [201]. 
Ceramide, has been also associated to the pathogenesis of the stroke 
[202, 203]; increased levels of ceramide have been observed in the 
hippocampus during the middle cerebral artery occlusion (MCAO) [203], 
and attenuation of SMase activity significantly reduced brain tissue injury 
in a mouse model of ischemic stroke [204, 205]. Beside all these 
evidences showed in the literature, the molecular mechanisms underlying 
the effect of ceramide in vascular tone regulation are still controversial, 
and they are most likely related to the concentration and further 
metabolization. Data more consistent and reproducible have been 
obtained in relation to the S1P. S1P regulates vascular tone acting 
through G-protein coupled receptors expressed on plasma membrane 
surface of both endothelial and smooth muscle cells of the vascular bed. 
Since circulating S1P is transported mainly by HDL [206], it has 
demonstrated the ability of HDL to induce vasodilation and migration of 
endothelial cells, as well as to serve a cardioprotective role, and this 
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beneficial propriety to reduce the risk of cardiovascular disease has been 
in part associated to the role as an S1P chaperone.  
S1P released in the extracellular environment can then interact with the 
receptor of the cells from where it has been synthesized and released 
(autocrine action) or on the same type of cells, which are peripheral from 
its origin site (paracrine). There are 5 types of S1P GPCRs named 
S1PR1, S1PR2, S1PR3, S1P4R, S1PR5. While S1PR4 is particularly 
expressed in the lung and lymphoid system and S1PR5 is predominately 
in brain tissues, S1PR1, S1PR2 and S1PR3 are three main receptors 
mediating the S1P signaling in the vasculature. However, the localization 
of these receptors is different between vascular smooth muscle and 
endothelial cells. Indeed, S1PR2 and S1PR3 mainly regulated the 
signaling of S1P in smooth muscle cells [207], whereas endothelial cells 
predominately express S1PR1 [208]. Stimulation of receptors on smooth 
muscle layer is associated to a vasocontracturant response, however 
S1P3R and S1PR2 are GPCR coupled to different α subunits, indeed 
S1PR3 is a Gαq protein thus, upon it activation, increases the intracellular 
flux of Ca2+ leading to contraction [209] whereas S1R2 acts through a 
different molecular signaling since it is associated to a Gα12/13-coupled 
protein which is responsible of RhoA/Rho pathway activation and 
constriction of vascular smooth muscle cells [210]. On the contrary, 
endothelial S1PR1 is a Gαi-coupled receptor and its interaction activates 
the intracellular PI3K/Akt pathway. Akt is a kinase, which regulates 
several proteins through phosphorylation [211]. S1P/S1PR1 is associated 
to an increased phosphorylation eNOS in EC promoting vasodilatation 
through the eNOS/NO pathway [211]. Nevertheless the localization of S1P 
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receptors is not always the same in all the vessels, thus vascular effect of 
S1P depends on the vascular bed where it acts. 
Interaction of S1P with S1Pr has shown a clinical important role in the 
immunological process, indeed Fingolimod (FTY720), an orally active drug 
targeting 4 out 5 S1PRs, has been approved by FDA for treatment of 
multiple sclerosis. Pharmacologically, FTY720 acts as an agonist at four 
of the five S1P receptors, S1P1-3-4-5R and inhibits lymphocyte egress 
from secondary lymphoid organs [212]. Nevertheless, it has been 
observed that chronically treatment with FTY720 leads to S1PR1 
internalization and degradation; hence FTY720 was defined “functional 
antagonist [213]. Moreover, the activation of the receptors S1P1 in the 
cardiovascular system accounts for the transient effects of FTY720 on 
heart rate, on the atrio-ventricular conduction and the lasting effect on BP 
[214-218] 
Moreover, the interaction between S1P and its S1P1R appears of a great 
importance not only for the regulation of the vascular tone, but also 
because mediates angiogenesis, inhibition of apoptosis, chemotactic 
response and proliferation [219]. Indeed it has been demonstrated that 
low levels of plasma S1P, such as in absence of Sphk [220], ApoM [221] 
cause the break of S1P-S1PR1 interaction leading to an increase of 
vascular permeability. This confirm the importance of S1P signaling in 
maintain the physiological vascular homeostasis.  
One of the most relevant signaling regulated by S1P is the eNOS/NO 
pathway in endothelial cells. Several in-vitro studies have proved the 
ability of S1P in directly activate eNOS. Studies on fibroblast-like cell lines 
derived from monkey kidney tissue (COS-7 cells) transfected with both 
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eNOS and S1PR1 and then stimulated with the lipid molecule, showed 
that NO production was increased after stimulation with S1P, while didn’t 
mutated in the absence of S1PR1 [169]. These data have been then 
confirmed on Bovine Aortic Endothelial Cells (BAEC), where eNOS and 
S1P1R were physiologically expressed. Subsequently, from the same 
group of research it has also been discovered that S1PR1 activity is also 
regulated by Cav-1, as happen for eNOS enzyme. Indeed, in BAEC cells, 
the overexpression of Cav-1 leads to a decreased activation of eNOS 
following the stimulation of S1P. Moreover, S1P stimulation progressively 
caused a translocation of the S1PR1 from the plasma membrane 
microdomains, to caveolae where the bound with Cav-1 shouted down the 
signaling, acting as a negative feedback for a prolonged S1P stimulation 
[169]. Moving then the attention on an in-vivo model, endothelial vascular 
cells following chemical or mechanical stimuli are continue sources of 
different vasoactive mediators, such as NO, prostacyclin and also S1P. 
S1P through an autocrine or paracrine manner acts as a potent activator 
of eNOS through S1PR1 on vascular endothelial cells [211] of a 
magnitude comparable to acetylcholine and bradykinin. It is also known 
that eNOS is activated by mechano-trasduction signal, as the blood flow-
induced shear stress which, increase the release of NO from eNOS with 
consequent vasorelaxation [222]. Moreover recently different evidences 
have been accumulated regarding the involvement of S1P-S1PR1 
interaction in blood flow-induced vasodilation. Absence of S1PR1 in 
endothelial cells fails to induce vasodilatation in response to flow as well 
as eNOS phosphorylation [223]. This data has been also confirmed by the 
evidence that inhibition of S1PR1 with W146 reduced both vasodilation 
induced by the flow and NO production, suggesting that S1P- S1PR1 
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interaction plays the major role in the mechano-trasduction signaling 
regulated by the blood flow [224] 
S1P produced by the vascular wall also participates in the regulation of 
the myogenic tone. In rabbit posterior cerebral arteries it has been show 
that changes in the intraluminal vascular pressure are followed by an 
increase of S1P release, which acting of S1PR2 and S1PR3 on the 
smooth muscle cells, induces a Ca2+/Rho-mediated contraction of the 
vessels [210]. Moreover, overexpression of Sphk1 [225], and deficiency of 
S1P phosphohydrolase [226] increase the myogenic tone in resistance 
arteries, while the overexpression of S1P phosphohydrolase causes the 
opposite effects, confirming that S1P plays a significant role in the 
vascular tone regulation. Moreover, it has been reported that S1P is also 
involved in AngII-induced hypertension. AngII causes an increase of 
vascular tone and blood pressure through a biphasic Ca2+ entry in the 
vascular smooth muscle cells.  Sphk1 participates in the AngII-mediated 
activation of store-operated calcium channels (SOCs), indeed, Spk1-/- 
mice show lower blood pressure compare to WT mice after AngII-induced 
hypertension [227]. Although these findings, it is still difficult to associate 
the increase of the vascular tone during hypertension to the hyper-
activation of S1P-S1PR2 or S1P3R signaling, since it can be due also to a 







1.5 Aim of my study 
Recently, the research group of Prof Di Lorenzo demonstrated that 
S1PR1 is a key regulator of blood pressure and flow through endothelial 
S1P-S1PR1-eNOS stimulated autocrine signaling [224]. Furthermore, they 
discovered a novel mechanism by which endothelial sphingolipids 
biosynthesis is regulated identifying NogoB [224]. 
Nogo-B is a Reticulon (RTN) proteins localized in the tubular ER through 
two transmembrane domains. The large family of RTN proteins is 
composed by three major isoforms, RTN-4A, -4B and -4C, also called 
Nogo-A, -B and -C. While Nogo-A and -C are expressed in the central 
nervous system, Nogo-B is highly localized in blood vessels [224].  It has 
been demonstrated that NogoB has an inhibitory activity on SPT, indeed 
murine and human derived EC depleted of Nogo-B show a 40% increase 
of SPT activity compare to the control, while the lentiviral- mediated re-
expression of the protein restored the physiological activity of SPT in 
blood vessels [118]. Starting from these evidences, the group of research 
of Prof. Di Lorenzo demonstrated that Nogo B binds to and inhibits serine 
palmitoyltransferase (SPT), the rate-limiting enzyme of the de novo 
sphingolipids biosynthesis, thereby controlling local endothelial S1P 
production to impact vascular function, blood pressure [224] and heart 
failure[199] (Figure 1.5). Nogo-B ECKO mice were hypotensive and 
protected by AngII-induced hypertension; these effects were reverted by 
in vivo administration of myriocin, pharmacological inhibitor of SPT, which 




Figure 1.5 NogoB down-regulates the de novo sphingolipids biosynthesis 
by inhibition of SPT enzyme 
These findings established a strong foundation for further research on the 
role of sphingolipids in cardiovascular pathophysiology.  
It has been well established that endothelium is bathed in SL-enriched 
plasma, and it can recycle SL up-taken from plasma, as well as deriving 
from intracellular catabolism process. Thus, during my last year of PhD in 
Professor Di Lorenzo Lab, I have been interested in the role of endothelial 
de novo biosynthesis in preserving vascular homeostasis. In particular we 
focused our attention in the involvement of this pathway in vascular tone 
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and blood pressure regulation by using a novel conditional genetic mouse 






















2. MATERIALS AND METHODS 
 
2.1 Animals 
We carry out experiments on conditional mouse model lacking of Sptlc2 
subunit, or both Sptlc2 and NogoB protein, specifically in the endothelium, 
named ECKO-Sptlc2 and ECKO-NogoB-Sptlc2 
Mice lacking Sptlc2 specifically in endothelial cells (ECKO-Sptlc2) were 
obtained by crossing Sptlc2f/f mice with transgenic mice in which the VE-
cadherin promoter drives expression of tamoxifen-responsive Cre (VE-
Cad-CreERT2) [228] such that tamoxifen treatment selectively deletes the 
loxP-flanked (‘floxed’) region of Sptlc2 in endothelial cells. Mice from this 
strains were born with Mendelian frequencies. To induce Sptc2 deficiency 
in endothelial cells, male Sptlc2f/f-VE-Cad-CreERT2-positive and Sptlc2f/f-
VE-Cad-CreERT2-negative littermates were injected intraperitoneally (i.p.) 
with 15 mg/kg of tamoxifen daily for 5 d at the age of 7-8 weeks. The 
same protocol has been applied to generate mice lacking of Nogo and 
Sptlc2 specifically in endothelial cells using Nogof/f-Sptlc2f/f. In both cases, 
the extent of Cre-mediated excision of exon 2 and 3 of Sptlc2 and  Nogof/f-
Sptlc2f/f was confirmed by real-time PCR on endothelial cells isolated from 
mouse lungs and on endothelial cell and VSMC mRNA isolated from the 
thoracic aorta of Sptlc2f/f, Nogof/f-Sptlc2f/f mice and EC-deficient Sptlc2 and 
Nogo-Sptlc2 animals.  
In another set of experiments we used Sptlc2+/-mice, since Sptlc2-/- mice 
are embryonically lethal [229]. 
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The Weill Cornell Institutional Animal Care and Use Committee approved 
all animal experiments.  
2.2 Sphingolipid analysis by LC-MS/MS 
Plasma from ECKO-Sptlc2 mice and their littermates controls has been 
used for quantification of sphingolipids by LC-MS/MS. The levels of 
ceramide (Cer) species, sphingosine (Sph) and S1P were analyzed by the 
Lipidomics Analytical Core at the Medical University of South Carolina as 
previously described [230]. 
2.3 Blood pressure measurement 
Systolic blood pressure was measured in conscious ECKO-Nogo-Sptlc2, 
ECKO-Sptlc2 male mice and their littermates control after treatment with 
tamoxifen using the pneumatic tail-cuff method (MRBP System, Life 
Science, Woodland Hills, California). Animals were placed in a plastic 
chamber maintained at 34 °C and a cuff, with a pneumatic pulse sensor, 
was attached to the tail (Figure. 2.1 A). As the cuff is inflated of air, the 
circulating flow is progressively reduced until it is completely blocked (thin 
signal - Figure. 2.1 B). Then, as the air goes outside the cuff, blood starts 
again to flow and the first pressure felt by vessel’s wall represents the 
Systolic Blood pressure (SBP) (thick signal - Figure 2.1 B), the highest 
pressure of the artery corresponding to the contraction of the left ventricle 
during the systole to pump the blood in the peripheral circulation. Mice 
were trained for three days, then pressure was monitored for one week. 
Each day, three consecutive measurements were performed per mouse, 
and the values were averaged.  
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Figure 2.1 Tail-cuff system 
 
2.4 Vascular reactivity assessment through pressure myograph 
WT and Sptlc2+/-, as well as Sptlc2f/f and ECKO-Sptlc2 mice after 
tamoxifen treatment were sacrificed. Second order mesenteric arteries 
(MA) from ECKO-Sptlc2 were harvested, carefully cleaned from adhering 
tissue and mounted on micropipettes in a pressure myograph chamber 
(Danish MyoTechnology, Aarhus, Denmark); the orientation of the vessel 
in relation to the flow in vivo was maintained. Viability of the vessels was 
maintained using Krebs solution (in mM: NaCl 118, KCl 4.7, MgCl2 1.2, 
KH2PO4 1.2, CaCl2 2.5, NaHCO3 25 and glucose 10.1), at 37 °C and 
oxygenated (95% O2 and 5% CO2). Micropipettes were connected to a 
pressure interface, which regulated intraluminal pressure and flow. The 
vessel diameter was monitored in real time using a microscope connected 
to a digital video camera (IC Capture) and computer software with edge 








            
 
Figure 2.2 Pressure Myograph system 
 
MA were equilibrated for 30 min at 80 mm Hg, pre-constricted with PE (1 
µM) and a cumulative concentration-response curve of Ach (0.1nM-30uM) 
was performed to evaluate the integrity and the function of the 
endothelium. Normotensive vessels with less than 80% vasodilatory 
response to Ach were discarded. In order to evaluate the endothelium-
dependent vasodilation mediated by particular receptors expressed on the 
surface of endothelial cells, PE pre-constricted MA have been stimulated 
by: 
-­‐ Gαi-coupled receptor ligands, as S1P (1pM-30µM) and Thrombin 
(1µU/ml-30mU/ml); 
-­‐ Gαq-coupled receptor ligands, as Ach and Histamine (10nM-30µM); 
-­‐ Tyrosine-kinase receptors ligands, as VEGF (1µg/ml-30mg/ml) and 
Insulin (1pU/ml-3µU/ml). 
Moreover, endothelium-independent vasodilatation of ECKO-Sptlc2 MA 
has been assessed through concentration-response curve of 
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Isoprotenerol (10nM-30uM) and Sodium Nitroprussiate (10nM-30uM) on 
PE pre-constricted vessels while vasoconstriction has been evaluated 
through cumulative concentration-response curve of PE (1nM-30uM).  
Flow-mediated vasodilation on mesenteric arteries was measured using 
pre-contracted vessels arteries with a concentration of PE inducing 60% 
of the maximum vasoconstriction achieved in the concentration-response 
curve of PE, followed by a step wise increase of 25 µl/min of the 
intraluminal flow from 0 to 125 µl/min. Flow was maintained for 5 min at 
each step. 
In another set of experiments ECKO-Sptlc2 MA were incubated with N5-
(1-Iminoethyl)-L-ornithine dihydrochloride	  (L-Nio) as eNOS inhibitor 10uM 
for 15 minutes, and then vascular response to Ach and increase of flow 
has been assessed 
At the end of each experiment, a myogenic curve was performed in Ca2+-
free Krebs buffer supplemented with 1 mM EGTA. Myogenic tone (%) was 
expressed as [(D1 − D2)/D1] × 100, where D1 is the passive diameter in 
Ca2+-free Krebs buffer and D2 is the active diameter in complete Krebs 
buffer, at the same intraluminal pressure. 
Carotid vessels from Nogof/f-Sptlc2f/f and ECKO-Nogo-Sptlc2 mice were 
also mounted in Pressure Myograph system following the same 
standardization protocol. Cumulative concentration response curves of 
Ach (0.1nM-30uM) have been performed on PE 1uM pre-constricted 
vessels. Moreover, vasodilation in response to increase of intraluminal 
flow has been evaluated on pre-contracted vessels arteries with a 
concentration of PE inducing 60% of the maximum vasoconstriction 
135	  
	  
achieved in the concentration-response curve of PE. A step wise increase 
of 25 µl/min of flow has been performed from 0 to 800 µl/min. Flow was 
maintained for 5 min at each step. 
2.5 Bleeding assay 
Bleeding assay has been performed as previously demonstrated [231]. 
Coagulation time has been assessed on male and female ECKO-Sptlc2 
and their littermate control after 4/5 weeks and 6/7 weeks post tamoxifen 
treatment. Mice were anesthetized and placed on a heating plate in prone 
position (Figure 2.3 A). The tail was cut (≈ 1mm), immediately immersed 
in a 50ml Falcon tube filled with PBS 37° and the time of coagulation 
started to be monitored (Figure 2.3 B). Bleeding time is determined using 
a stop clock and monitoring each animal for 20 minutes. In order to detect 
any re-bleeding during the experiment, if bleeding on/off cycles occur, the 
sum of the bleeding times within the 20 minutes period is calculated and 







               
 
        
 
Figure 2.3 Bleeding assay 
 
2.6 Electron Mycroscopy analyses 
Males Sptlc2f/f and ECKO-Sptlc2 mice were deeply anesthetized with 
sodium pentobarbital (150 mg/kg, I.P.). Mice were placed chest up onto 
the silicon pad and pin the paws to check if it was completely 
anesthetized. Then, whiteout injuring the underlying organs, the chest was 
opened by a cut until the heart was visible. Heart was grabbed with the 
hemostatic forceps and a needle was inserted in the left ventricle without 
puncturing through in order to perfuse the heart using a pump to a speed 
of about 9ml/min. Perfusing solution was composed by: (1) 10–15 ml 0.9% 
saline containing 2% heparin; (2) 50 ml of 3.75% acrolein and 2% 
paraformaldehyde in 0.1 M phosphate buffer (PB; pH 7.4); and (3) 200 ml 





were collected, cleaned from the adherent tissue and post-fixed in 2% 
paraformaldehyde in PB for 30 min, and then transferred into PB. Sections 
were stored in cryoprotectant solution (30% sucrose and 30% ethylene 
glycol in PB) at 20 °C. Carotid sections were then analyzed through 
Electron Microscopy (EM) to see caveolae distribution in the endothelial 
layer. 
2.8 Statistical analysis 
Data are expressed as mean ± s.e.m. One-way or two-way ANOVA with 
post hoc Bonferroni's test was run for all statistical analyses except where 
a Student's t-test analysis was used. Differences were considered 
statistically significant when P < 0.05. All tests were two-sided. GraphPad 
Prism software (version 5.0, GraphPad Software, San Diego, CA) was 
used for all statistical analysis. The s.d. considered for the calculation was 
estimated on the basis of previous published studies using the tail-cuff 
system to measure blood pressure in mice and by preliminary 










3.1 The lack of endothelial SPT increases BP 
Mice lacking of Sptlc2 expression in endothelial cells have increased BP 
then control mice at baseline (Figure 3.1 A), suggesting that endothelial-
derived sphingolipids play an important role in preserving vascular 
homeostasis. 
                                       
Figure 3.1 Systolic blood pressure of (A) ECKO Sptlc2 104.9±0.62 vs 123.4±1.53, control vs 
ECKO Sptlc2, n=5mouse/group, **p<0. 01. Statistical significance was determined by unpaired 
T-test. 
 
3.2 The loss of endothelial SPT reduces plasma levels of 
sphingosine and S1P 
The lack of Sptlc2 subunit in EC induces a reduction of plasma levels of 
different ceramide species as C16-, C22- and C24-ceramide (Figure 3.2 
A, B). Moreover, plasma from ECKO-Sptlc2 mice presents a significantly 
decrease of dihydrosphingosine-1 phosphate (dhSph-1P), S1P as well as 
Sphingosine (Sph) levels compared to the control (Figure 3.2 A, B), 
suggesting that reduction of endothelial SPT activity decreases 



















                          
	  	  	  	  	  	  	  	  	  	  	  	   
                             
Figure 3.2. (A-B) Total ceramide species, sphingosine and S1P levels in plasma from ECKO-
Sptlc2 mice and their littermates control measured by LC-MS (n≥9 mouse/group, *p<0.1, 









































































































































3.3 The reduction of sphingolipids production affects the number 
and the size of caveolae in carotid arteries. 
It is well known that sphingolipids are important components of plasma 
membrane microdomains, distinguished in caveolar and non caveolar lipid 
rafts. In order to understand whether the reduction of endothelial 
sphingolipids production could leads to morphological alterations of 
plasma membrane, we performed EM analysis of carotid arteries (Figure 
3.3 A-B). The size of caveolae in the basolateral and luminal membranes 
of the endothelium of ECKO Sptlc2 is reduced compared to the control 
(Figure 3.3 A-B-C). On the contrary, the number of caveolae is 
significantly increased (Figure 3.3 D-E-F), probably due to a 
compensatory mechanism. The lack of SPT activity in endothelial cells 
could reduce sphingolipids in plasma membrane and impair their relative 
abundance with cholesterol, altering lipid raft microdomains 
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Figure 3.3 (A) Electron microscopy analysis of caveolae expressed on carotid arteries 
endothelial layer from Sptlc2ff and ECKO-Sptlc2 mice. (B) Size of caveolae in (C) basolateral 
and (D) luminal endothelial cells plasma membrane. (E) Number of caveolae in (F) basolateral 
and (G) luminal endothelial cells plasma. Data are expressed as mean± SEM. (B-F) 
Statistical significance was determined by Unpaired t-test, *P<0.1, **P<0.01, ***P<0.001 
ECKO Sptlc2 vs. Sptlc2f/f. 
 
3.4 Endothelial-dependent vasodilatation is impaired in ECKO-Sptlc2 
resistance arteries.   
Ligand-mediated activation of GPCR and TK receptors in EC mainly 
induce vasodilation via eNOS-derived NO [233]. GPCR and TK receptors 
are localized in lipid rafts, specialized sphingolipid-enriched microdomains 
of the membrane functioning as platform for transduction signaling [136, 
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specific microdomains-linked signaling pathways, we assessed the 
endothelial-dependent vasodilation induced by different GPCRs and TK 
receptors agonists on ECKO-Sptlc2 and Sptlc2f/f MA. We demonstrate 
that S1P- and thrombin-mediated vasodilatation, through Gαi-coupled 
S1PR1 and PAR1 respectively, are significantly reduced in ECKO-Sptlc2 
compared the control MA (Figure 3.4 A-B). We also showed  that 
vasodilation of MA in response to insulin and VEGF through IR and 
VEGRF2, TK receptors, was markedly reduced in absence of endothelial 
Sptlc2 (Figure 3.4 C-D). On the contrary, Ach and histamine Gαq-
mediated vascular response  were not affected in the two groups (Figure 
3.4 E-F). Thus, reduction of SPT activity in EC causes a decrease of Gαi-
coupled and TK receptors-mediated vasodilatation, whereas vascular 
response via Gαq-coupled receptors remains unaltered.  
It has been reported that depletion of membrane cholesterol with Methyl-
β-cyclodextrin decreases lipid order and fluidity, blunting the intracellular 
signaling in response to shear stress [234]. We demonstrated that 
absence of endothelial Sptlc2 decreases flow-mediated vasodilatation in 
MA (Figure 3.4 G), suggesting that lipid order of endothelial membrane is 
associated to shear-stress-sensing response [234, 235]. 
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Figure 3.4 (A-B) Cumulative concentration-response curve of Gαi-coupled receptor on 
mesenteric arteries: (A) S1P-induced vasodilatation (n≥5 MA/group, n≥5 mouse/group, 
***p<0.001) and vascular response of (B) Thrombin (n≥7 MA/group, n=≥4 mouse/group, 
***p<0.001). (C-D) Tyrosine-kinases induced vasodilatation: vascular response of (C) VEGF 
(n≥5 MA/group, n≥3 mouse/group, ***p<0.001) and Insulin (n≥4 MA/group, n≥4 mouse/group, 
***p<0.001). Endothelial-dependent vasodilatation mediated by Gαs-coupled receptor; (E) Ach 
(n=12) and (F) Histamine (n≥4 MA/group, n≥3 mouse/group, ***p<0.001) vascular response 
(G) Flow-induced endothelial-dependent vasodilatation in ECKO-Sptlc2 mice vs Sptlc2f/f. Data 
were expressed as the mean ± s.e.m.  ***P<0.001 compared to control mice. Statistical 
significance was determined Two-way ANOVA followed by Bonferroni’s post-test. 

















































































C	   D	  




3.5 eNOS-NO pathway is preserved in ECKO Sptlc2 MA 
We used L-Nio as pharmacological inhibitor of eNOS enzyme to evaluate 
the contribution of NO in the endothelial-dependent vasodilatation to Ach 
and flow in ECKO-Sptlc2 mice. Ach-induced vasodilatation is significantly 
decreased following L-Nio, in both ECKO and control MA to the same 
extent (Fig 3.5 A). Likewise, L-Nio equally reduces flow-mediated 
vasodilatation in both ECKO Sptlc2 and control MA (Fig 3.5 B), suggesting 
that in absence of SPT eNOS-NO pathway still gives a contribution in the 
vasodilatation.  
 
                  
Figure 3.5 (A) Cumulative concentration-response curve of Ach (n≥9 MA/group, (n≥8 
mouse/group, ***p<0.001) and (B) flow-mediated vasodilatation (n≥9 MA/group, n≥8 
mouse/group,  ***p<0.001) after incubation of L-Nio 10uM. Data were expressed as the mean 
± SEM  ***P<0.001 compared to control mice. Statistical significance was determined by (A-B) 
Two-way ANOVA followed by Bonferroni’s post-test 
 
3.6 Vascular smooth muscle cell-dependent vasodilatation is 
retained in absence of endothelial SPT 
To assess that guanylyl cyclase-dependent cGMP production is preserved 
in absence of endothelial SPT activity, we employed the Sodium 
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Nitroprussiate (SNP), a NO-donor. SNP-induced vasodilatation is not 
impaired in absence of endothelial SPT (Figure 3.6 A).  
Next, we evaluated β2-receptor mediated VSMC relaxation. As shown in 
Figure 3.6 B the vascular response to Isoprotenerol was not altered by the 
loss of endothelial SPT (Figure 3.6 B) suggesting that cGMP production 
and its vasorelaxing signaling in VSMC are preserved.  
 
                               
Figure 3.6 Cumulative concentration response curves of (A) Isoprotenerol and (B) SNP -
induced vasodilation (n≥5 MA/group, n≥4 mice group). Data were expressed as the mean ± 
s.e.m.  ***P<0.001 compared to control mice. Statistical significance was determined Two-way 
ANOVA followed by Bonferroni’s post-test 
 
3.7 The lack of SPT increases vasoconstriction in response to 
mechanical, but not, pharmacological stimuli.  
We assessed the vasoconstriction to pressure and pharmacological 
stimuli in MA from ECKO-Sptlc2 and Sptlc2f/f mice. MA vasoconstriction in 
response to PE is preserved in absence of endothelial SPT (Figure 3.7 A).  
Next, we assessed the myogenic response of MA, which represents the 
spontaneous contraction of the vessel to the increase of intraluminal 





































pressure to maintain constant the flow. First, we evaluated the response 
of the vessels to the increase of intraluminal pressure in complete (active 
tone) and Ca2+-free Krebs buffer (passive tone). Physiologically, the 
increase of intraluminal pressure induces vascular contraction, whereas in 
Ca2+-depletion conditions this response is abrogated and vessels 
diameter progressively increases. ECKO-Sptlc2 show a significantly 
increase of the active tone in response to pressure compared to control 
MA (Figure 3.7 C), whereas there are no differences in the passive inner 
diameter (Figure 3.7 D), suggesting that myogenic tone is significantly 
higher in absence of endothelial SPT (Figure 3.7 E).  
Altogether these data suggest that endothelial-derived sphingolipids are 
essential to maintain a physiological vascular tone in response to 
pressure, but dispensable to preserve vascular structure. 
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Figure 3.7 Cumulative concentration-response curve of PE expressed as (A) % Contraction 
and (B) Inner Diameter (n=23 MA/group, n=13 mouse/group, **p<0.01).  (C) Active and (D) 
Passive diameter and (E) Myogenic tone (%) in response to a stepwise increase of 
intraluminal pressure  (n=8 MA/group, n=5 mice/group, , **p<0.1). Statistical significance was 
determined Two-way ANOVA followed by Bonferroni’s post-test.    
                                        
3.8 Heterozygous mice for Sptlc2 (Sptlc2+/-) show endothelial 
dysfunction and increase in BP.  
SBP was significantly higher in Sptlc2+/- mice compared to WT (Figure 3.8 
A). Flow- and Ach-mediated vasodilation was reduced in MA from Sptlc2+/- 
mice vs. control (Figure 3.8 B-C). Moreover, systemic reduction of 
sphingolipids de novo biosynthesis increased the myogenic tone of MA, 
whereas vasoconstriction in response to PE was not altered (Figure 3.8 D-








































































E). These results recapitulate the phenotype observed in ECKO-Sptlc2 
mice suggesting that most likely is the endothelial SPT activity to play a 
major role in blood pressure homeostasis.  
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	    
Figure 3.8 (A) Systolic Blood pressure of Sptlc2+/- mice compare to the WT (Mean value: 
112.133±2.59 vs 128.9±2.58, WT vs Sptlc2+/-, n=3mouse/group, **p<0.01). Vasodilation of MA 
induced by (B) cumulative concentration response curve of Ach (n≥6 MA/group, n≥4 
mouse/group, **p<0.01), and (C) flow expressed as inner diameter (n≥4 MA/group, n≥3 

























































































of PE (n≥6 MA/group, n≥4 mouse/group) and (E) increase of intraluminal pressure (n≥6 
MA/group, n≥3 mouse/group, *p<0.1). Statistical significance was determined by (A) unpaired 
T-test and (B-E) Two-way ANOVA followed by Bonferroni’s post-test. 
 
3.9 Nogo-B deletion does not restore endothelial function in ECKO-
Sptlc2 mice 
Professor Di Lorenzo’s Lab identified Nogo B as negative regulator of the 
de novo sphingolipids biosynthesis. They demonstrated that endothelial 
absence of Nogo B in the ER up-regulates SPT and thus local endothelial 
sphingolipids, leading to protection against hypertension [224] and heart 
failure. In order to demonstrate the main role of SPT in this vascular 
phenotype, we performed experiments on ECKO-NogoB-Sptlc2 mice.  
Our data show that ECKO-NogoB-Sptlc2 mice have increased SBP 
compare to control (Figure 3.9 A). Moreover, assessment of vascular 
reactivity in carotid arteries shows that flow-induced vasodilatation (Figure 
3.9 B), but not Ach (Figure 3.9 C), is significantly reduced following 
endothelial Nogo and Sptlc2 deletion suggesting that the vascular 
protective effect related to endothelial absence of Nogo is directly due to 
SPT activation.  

















                     	    
Figure 3.9 (A) Systolic blood pressure of ECKO Nogo-Sptlc2, compared to their littermates 
control (Mean value 108.66±5.186 vs 124.930±2.17, control vs ECKO Nogo-Sptlc2, n=5 
mouse/group, ** p<0.01). Vasodilatation induced by (B) flow (n=5 vessels/group, n=5 
mouse/group, ***p>0.001) and (C) cumulative concentration-response curve of Ach (n=5 
vessels/group, n=5 mouse/group) assessed on carotid vessels from ECKO NogoB-Sptlc2 
mice. Data were expressed as the mean ± SEM. Statistical significance was determined by (A) 
unpaired T-tes and (B-C) Two-way ANOVA followed by Bonferroni’s post-test.         
 
3.10 Absence of SPT activity in endothelial cells accelerates the 
physiological coagulation process  
Endothelial layer plays an important role in the hemostasis. Since our 
collected data suggest that reduction of endothelium-derived sphingolipids 
affects ECs function, we assessed whether the absence of SPT affects 
the coagulation process. Bleeding assay performed on males and females 
ECKO-Sptlc2 and Sptlc2ff showed that endothelial loss of SPT activity 
progressively reduces the coagulation time after tail amputation (of ≈ 
0.3mm) (Fig. 3.10 A-B), suggesting that reduction of endothelial-
sphingolipids production causes an alteration of endothelial function 
towards a pro-thrombotic effect. 







































                                
Figure 3.10 Time of coagulation in (A) males (n≥3 mouse/group) and (B) females (n≥5 
mouse/group) Sptlc2ff and ECKO-Sptlc2 at different time point from tamoxifen treatment. Data 
are expressed as mean± SD. (A-B) Statistical significance was determined by One way 

























































The pathogenesis of hypertension, the leading cause for myocardial 
infarction, heart failure and stroke [236], is multifactorial and highly 
complex. Despite current therapies, BP management does not reach a 
satisfactory outcome in all the patients, suggesting the need for alternative 
therapeutic targets and a better understanding of underlying mechanisms. 
The results of this study reveal sphingolipid de novo biosynthesis as a 
necessary pathway to preserve endothelial cell-dependent regulation of 
vascular tone and BP homeostasis. Our data identify endothelial-derived 
sphingolipids as key regulatory molecules of endothelial cell function. 
Specifically, we identified an important role of locally produced SL in 
endothelial-mediated vasodilation following the activation of Gαi-coupled 
and TK receptors, as well as by flow, leading to a significant increase of 
systolic BP in ECKO Sptlc2 mice. 
SLs are important component of the eukaryotic plasma membrane, and 
contribute to preserve the integrity and fluidity of membranes. Every cell of 
our body can synthetize “de novo” sphingolipids. Furthermore, SL can be 
uptaken by the cells and via recycling pathway can be transformed in 
higher order SL such as SM and GSL. However, this pathway is not 
sufficient to compensate the de novo biosynthesis as endothelial cells 
lacking SPT failed to maintain a proper control of vascular tone and BP 
homeostasis.  
The role of SL in BP homeostasis has been the subject of intense studies. 
S1P, ceramide, as well as sphingosine, represent the best characterized 
molecules of this class, and have been implicated in pathogenesis of 
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hypertension, however specific molecular mechanisms are poorly 
understood.   
Recently, Di Lorenzo’ group demonstrated that endothelial-derived S1P is 
a key regulator of blood flow and pressure, through S1PR1-eNOS-NO 
autocrine signaling [224]. Furthermore, they discovered that a novel 
regulatory endothelial sphingolipids de novo production, mediated by a 
membrane protein of the endoplasmic reticulum called Nogo, appears to 
control local endothelial S1P production and impacts vascular function, 
blood pressure (BP) [224] and also heart function [199]. Considering that 
the endothelium is bathed in SL-enriched plasma, and it can recycle SL 
uptaken from plasma, as well as deriving from intracellular catabolism 
processes, it was surprising the critical role of de novo SL production in 
preserving vascular homeostasis. These findings suggest also that down 
regulation of endothelial SL biosynthesis contribute or exacerbates the 
onset of a cardiovascular disease, such as hypertension.  Thus, we 
hypothesized that ablation of endothelial SPT activity by genetic approach 
would trigger endothelial dysfunction and hypertension.  
To test this hypothesis, we deleted Sptlc2 subunit specifically in EC. In 
ECKO-Sptlc2 mice, plasma Sph and S1P levels were significantly 
reduced, an effect that correlated with increased blood pressure at 
baseline.  Vasodilation of MA in response to flow and Ach was impaired, 
with the latter manifesting only at later time point post-tamoxifen 
treatment. Furthermore, endothelial Sptlc2 deletion led to an increase of 
vasoconstriction in response to intraluminal pressure. These entire 
patterns have been also confirmed in heterozygous Sptlc2+/- mice. These 
findings are complimentary to the up regulation of SPT activity in the 
endothelium, which preserves endothelial dysfunction and blood pressure 
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homeostasis. Furthermore, deletion of endothelial NogoB in ECKO-Sptlc2 
mice does not restore SBP to a physiological range, neither ameliorates 
the flow-mediated vasodilatation which is drastically reduced in ECKO-
NogoB-Sptlc2 carotid arteries, suggesting that the essential role of Nogo-
B is inhibits SPT to impact vascular function and BP.  
The loss of SPT also leads to a prothrombotic endothelium. Endothelium 
regulates the coagulation exerting both an antithrombotic and pro-
coagulant activity, and the balance between these two processes is a 
critical in determining the formation of thrombus, its propagation and its 
dissolution. Mice ECKO Sptlc2 showed a significant increase in the 
coagulation time in the tail bleeding assay, suggesting an important role of  
SL de novo biosynthesis in preserving an anti-thrombotic function of the 
endothelium.  
 
In the plasma membrane, sphingolipids dynamically interact with 
cholesterol to form lipid raft microdomains [135], playing an important role 
in endocytosis, cells trafficking [145, 237] and signaling  [137]. Endothelial 
cells are characterized by membrane invaginations called caveolae, 
enriched in SL and cholesterol and hosting multiple receptors [136, 145, 
238]. Firstly, electron microscopy analysis showed an increase in the 
number of caveolae and decrease in their size in EC of ECKO-Sptlc2 
carotid arteries vs. control. However, the changes were moderate, 
suggesting that the loss of SPT did not induced profound morphological 
changes in the endothelium, but most likely altered functions associated to 
the plasma membrane. 
Caveolae defined caveolar lipid rafts, and are distinct from non caveolar 
lipid rafts, which are enriched in SLs [238]. It has been reported that Gαq-
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coupled and TK receptors are predominantly expressed in endothelial 
cells caveolae [158, 238-240], whereas others, such as Gαi- and Gαs-
coupled receptor are more abundant in the non-caveolar compartment of 
lipid raft [238]. Since guanylyl cyclase-cGMP pathway was preserved in 
the VSMC of ECKO-Sptlc2, we assessed whether the reduction of 
endothelial-produced SL alters lipid rafts composition, hence receptor-
mediated signaling. Thus, we tested the vascular endothelial response to 
the activation of different GPCRs as well as tyrosine receptors known to 
be located/distributed in the lipid rafts [136], as readout of the function of 
the receptors, assuming no differences in the expression levels. Indeed, 
our findings demonstrated that only the activation of Gαi-associated 
receptors (S1PR1 and PAR1) and tyrosine kinase receptor (VEGFR2, IR) 
is impaired in ECKO-Sptlc2, whereas Gαq-mediated effect is unaffected. A 
study of Igarashi and colleagues reported that following S1P stimulation, 
S1PR1 translocases in caveolae, where is inhibited by Cav-1 [241], a 
membrane protein localized in the caveolae and regulating the activation 
of different signaling pathways. Knocking down of Cav-1 in BAEC led to 
an up-regulation of S1P-S1PR1 signaling. We do not know whether the 
loss of SPT alters the expression of Cav-1 in the EC, however, Cav-1 also 
inhibits eNOS and we do not find any alteration in basal and stimulated 
NO, suggesting that this molecular mechanism is not accountable for the 
phenotype. 
An alternative molecular mechanism could be that SPT ablation changes 
membrane lipid composition, altering the dynamic distribution of the 
receptors among different plasma membrane microdomains, necessary to 
control the switch from inactive to active states of the receptors, and vice-
versa.  For instance, the binding of VEGF to VEGFR2 induced the 
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dimerization and activation of the receptors by auto-phosphorylation of 
their cytosolic domains [242]. It is possible that the fluidity of lipid bilayer 
can affects the rates of lateral diffusion and mobility of the receptors in the 
membrane [243, 244]. Insulin receptor (IR), on the contrary, is expressed 
in the caveolae as dimer [245]; upon insulin binding, IR undergoes a 
conformational change that allows trans-phosphorylation of the catalytic 
sites on multiple tyrosine residues, which is essential for the receptor 
activation and development of intracellular signaling [246]. Changes in 
cholesterol and sphingolipid levels, particularly GSL, impair the 
localization of the IR in caveolar lipid rafts [190]. Moreover, mechanical 
stimuli, such as shear stress, pressure and circumferential stretch, 
modulate EC morphology and functions by activating mechano-sensors 
on plasma membrane and developing intracellular signaling [247, 248]. 
Thus, it is reasonable to speculate that reduction in flow-induced 
vasodilation in ECKO-Sptlc2 MA could be associated to possible changes 
in plasma membrane composition rather than impairment in eNOS/NO 
pathway, since we did not find any differences in Ach-vascular response, 
in presence and absence of L-Nio. 
 
In conclusion, our findings suggest that sphingolipids are important in the 
regulation of endothelial-dependent BP homeostasis. Alterations of their 
levels below or above a physiological range leads to alteration in vascular 
tone and BP regulation [249] (Figure 4.1). There are many studies that 
associated high levels of plasma sphingolipids to a hypertensive state 
[250]. However, our data demonstrate that down regulation of endothelial 
de novo sphingolipid biosynthesis, by deletion of SPT, increases BP and 
impairs endothelial cell functions. Endothelial-derived SL are of critical 
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importance to maintain blood pressure homeostasis and to preserve 
endothelial cell functions, including vascular tone and blood fluidity 
regulation. However, further investigations are needed in order to dissect 
the underlying molecular mechanisms of the phenotype observed in mice 
lacking endothelial SPT.  
    
     










Figure 4.1 Alteration of SL levels below or above the physiological range alters vascular 
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